

RAM.CS.03/2026

27 March 2025

Subject: Invitation to the 2026 Annual General Meeting of Shareholders

To: Shareholders of Ramkhamhaeng Hospital Public Company Limited

Enclosures: 1. Copy of the minutes of the 1/2025 Extraordinary General Meeting of Shareholders
2. 56-1 One Report for the year 2025 (QR Code)
3. Guidelines and Required Documents for registration to attend the meeting
4. Information of the directors as Proxy holder
5. Information of the directors who retired by rotation
6. Information of the proposed auditors for the year 2026
7. Map of the shareholders' meeting venue
8. Company's Articles of Association related to the Shareholders' Meeting
9. Data Privacy Notice
10. Proxy form A, B and C

According to the Board of Directors' meeting of Ramkhamhaeng Hospital Public Company Limited (hereinafter referred to as the "Company") has resolved to convene the 2026 Annual General Meeting of Shareholders ("2026 AGM") on Thursday, April 30, 2026, at 13.00 hrs. at Meeting Room, 10th Floor, building 3 Ramkhamhaeng Hospital, 436 Ramkhamhaeng Rd., Huamak Sub-district, Bangkok District, Bangkok 10240, to consider the following agenda items:

Agenda 1: To consider and certify the minutes of meeting of the Extraordinary General Meeting of Shareholders No. 1/2025 on June 10, 2025

Objective and Rationale: The Company held Extraordinary General Meeting of Shareholders No. 1/2025 on June 10, 2025, with the minutes of the meeting appearing in Enclosure 1, in which the Company has published a copy of the said minutes of the meeting on

the Company's website (<http://www.ram-hosp.co.th>) for shareholders to acknowledge and verify the correctness. The meeting minutes were sent to the Stock Exchange of Thailand and the Ministry of Commerce within the time frame specified by law.

The Board of Directors' Opinion: The Board of Directors has considered that the minutes of the meeting have been recorded accurately and completely. Therefore, it is deemed appropriate to propose to the shareholders' meeting to consider and certify the minutes of the meeting.

Required Votes: This agenda requires the majority vote of shareholders attending the meeting and casting their votes.

Agenda 2: To acknowledge the report on the results of operations for the year 2025

Objective and Rationale: The Company has prepared a summary of the 2025 results of operations and the Board of directors' reports and the detailed 56-1 One report in *Enclosure 2*, which the Board of Directors has considered and is of the opinion that it is correct, complete, sufficient. Therefore, it is proposed to be presented at the shareholders' meeting for acknowledgment.

The Board of Directors' Opinion: The Board of Directors has deemed it appropriate to propose to the shareholders' meeting to acknowledge the Company's results of operations in 2025. This agenda is for acknowledgment; therefore, no voting is required.

Agenda 3: To consider and approve the Financial Statements for the year ended 31 December 2025 which have been audited by an authorized auditor

Objective and Rationale: In accordance with the Public Limited Companies Act B.E. 2535, as amended which prescribes that the Company has prepared the financial statements at the end of the Company's fiscal year which has been certified by the auditor prior to propose the shareholders' meeting for consideration and approval. The details are shown in the 56-1 One Report for the year 2025 in *Enclosure 2*.

Audit Committee's Opinion: The Audit Committee has considered and reviewed the Financial Statements as of December 31, 2025, which were audited and certified by the Company's certified auditor and deems it appropriate to propose the Board of Directors to propose the shareholders' meeting for consideration and approval.

The Board of Directors' Opinion: The Board of Directors has deemed it appropriate to propose to the 2026 AGM to consider and approve the financial statements for the fiscal year ended December 31, 2025, which have been audited by the certified auditor and reviewed by the Audit Committee as accurate. Additionally, the company's board of directors has also approved the financial statements, which are summarized as follows:

(Unit: Baht)

Items	Consolidated Financial Statements	
	As of December 31, 2025	As of December 31, 2024
Total Assets	63,748,083,467	41,290,455,867
Total Liabilities	23,957,727,023	14,350,350,270
Total shareholders' equity	39,790,356,444	26,940,105,597
Total revenues	15,157,704,469	10,228,686,552
Profit from operating activities	1,629,974,875	1,255,713,468
Profit for the year	3,047,559,765	692,748,280
Earnings per share (baht/share)	2.33	0.61

Required Votes: This agenda requires the majority vote of shareholders attending the meeting and casting their votes.

Agenda 4: To consider and approve the dividend payment for the year 2025

Objective and Rationale: In accordance with the Public Limited Companies Act B.E. 2535, as amended which prescribes that the Company is required to allocate a portion of annual net profit as a reserve fund in the amount not less than 5 percent of the annual net profit less the accumulated loss thought forward (if any) until the reserved fund attains the amount not less than 10 percent of the Company's registered capital. The company has fully

allocated the legal reserve as required by law, and therefore, there is no need to allocate additional reserves.

The Company would like to propose that the shareholders' meeting consider the approval of a dividend payment for the year 2025 at the rate of Baht 0.10 per share, totaling Baht 120,000,000, or equivalent to 9.17% of the Company's net profit from its separate financial statements

Although the Company has a policy to pay dividends at a rate of not less than 20% of the Company's net profit from its separate financial statements (it is *not in accordance with such policy*), the determination of the dividend for this year has been made with careful consideration of the Company's future investment plans, the need to maintain an appropriate level of financial liquidity, as well as the management of risks arising from uncertainties in economic and industry conditions, including compliance with financial covenants under agreements with financial institutions, in order to ensure the Company's sustainable long-term growth.

The Board of Directors' Opinion: The Board of Directors has considered it is appropriate to propose to the shareholders' meeting to consider and approve the dividend payment for the year 2025, at the rate of 0.10 Baht per share, totaling Baht 120,000,000. The details of the dividend payment compared with the previous year are summarized as follows:

	2025	2024
Earnings per share (baht/share) from the separate financial statements	1.09	0.98
Dividends per share (baht/share) from the separate financial statements	0.10	0.40
Dividends Payout Ratio (%)	9.17	40.81

The record date for determining the shareholders entitled to receive the dividend will be March 26, 2026. The dividend payment is scheduled to be made on May 29, 2026, subject to approval by the 2026 Annual General Meeting of Shareholders.

Required Votes: This agenda requires the majority vote of shareholders attending the meeting and casting their votes.

Agenda 5: To consider and approve the election of directors who retired by rotation

Objective and Rationale: According to the law and the Company’s articles of association stipulate that one-third (1/3) of the total number of directors shall be retired at every annual general meeting of shareholders. If the number of directors cannot be divided precisely into three parts, the number of retired directors shall be as close to one-third as possible. The Company currently has 15 directors; in 2026, there will be 5 directors retired by rotation, as follows:

Director	Position
1. Dr. Rukkagee Kanjanapitak, PH.D.	<ul style="list-style-type: none"> ▪ Director ▪ Member of Nomination and Remuneration Committee ▪ Member of Risk Management and Investment Committee and ▪ Member of Executive Committee
2. Dr. Suthee Leelasetakul, M.D.	<ul style="list-style-type: none"> ▪ Director and ▪ Member of Executive Committee
3. Dr. Wiroj Onganunkun, M.D.	<ul style="list-style-type: none"> ▪ Director
4. Mr. Wacharalak Tunskul	<ul style="list-style-type: none"> ▪ Independent Director and ▪ Chairman of Audit Committee
5. Miss Kittiyarat Jirojdamrongchai	<ul style="list-style-type: none"> ▪ Independent Director and ▪ Member of Audit Committee

The Company provided an opportunity for shareholders to nominate qualified candidates for consideration for election as directors in advance, from September 30, 2025 to December 31, 2025, in accordance with the criteria published on the Company’s website. Upon the expiration of the aforementioned period, no shareholder submitted any nomination for consideration for election as a director.

The Nomination and Remuneration Committee’s opinion: The Nomination and Remuneration Committee “NRC” (excluding the interested directors) has conducted the careful and diligent nomination process of qualified individuals, considering the qualifications required by law, the company’s Articles of Association, and relevant requirements. Additionally, the process will consider the knowledge, capabilities, expertise, and experience suitable for the

company's business, as well as the overall diversity of the board's qualifications. The NRC is of the opinion that the directors who retired by rotation as listed above, possess full qualifications required under the company's nomination criteria and process. This is in accordance with the Public Limited Companies Act and the relevant regulations issued by the Capital Market Supervisory Board,

It is deemed appropriate for the meeting of the Board of Directors to consider proposing to the Annual General Meeting of Shareholders for the election of the company's directors as follows.

The Board of Directors' Opinion: The Board of Directors excluding the interested directors, has carefully considered and approved recommendation of the Nomination and Remuneration Committee. Therefore, it is deemed appropriate to propose to the 2026 AGM to consider and approve the re-election of five (5) directors who retired by rotation, these directors are: 1) Dr. Rukkagee Kanjanapitak 2) Dr. Suthee Leelasetakul 3) Dr. Wiroj Onganunkun 4) Mr. Wacharalak Tunskul and 5) Miss Kittiyarat Jirojdamrongchai, to continue serving as directors and members of subcommittees for another term

The Board of Directors, excluding interested directors, has considered and concurred with the Nomination and Remuneration Committee that the independent directors, namely Mr. Wacharalak Tunskul and Miss Kittiyarat Jirojdamrongchai, possess the qualifications of Independent Directors as required by the relevant laws and in accordance with the prescribed qualifications of the Independent Directors of the Company and has full capacity to express their opinions independently.

Information of individuals nominated as the directors who retired by rotation has been provided to the shareholders together with this invitation appearing in Enclosure 5

Required Votes: This agenda requires the majority vote of shareholders attending the meeting and casting their votes.

Agenda 6: To consider and approve the directors' remuneration for the year 2026

Objective and Rationale: According to the law and the Company's articles of association stipulate that directors are entitled to receive remuneration in the form of salary, meeting allowances, allowances, and bonuses, based on the company's performance,

responsibilities, and the performance of the board of directors. Therefore, it is deemed appropriate to propose to the shareholders' meeting for approval of the directors' remuneration for the year 2026, which has been decreased from the previous year, as follows:

Monetary Remuneration

1. Monthly Remuneration Paid to the Company's directors (with *a proposed change in the payment structure* from an aggregate annual payment of 52,000,000 baht for all member of the Board of Directors to monthly payments with amounts specified according to each director's position), as well as to one sub-committee, namely the Group Executive Committee.

2. Meeting Allowance Paid to the Company's directors and to members of 4 sub-committees: 1. Audit Committee 2. Nomination and Remuneration Committee 3. Risk Management and Investment Committee and 4. Corporate Governance and Sustainability Committee. Such fees are payable to those who attend meetings in accordance with the prescribed rates. The Group Executive Committee will not receive meeting attendance fees.

2025			2026 (Propose)		
Committee / Position	Yearly Remuneration	Meeting Allowance	Committee / Position	Monthly Remuneration	Meeting Allowance
	(Baht/Year)	(Baht/Time)		(Baht/Month)	(Baht/Time)
Board of Directors			Board of Directors		
Chairman and Director (Executive, Non-Executive and Independent Director)	52,000,000	-	Chairman	40,000	-
			Director (Executive, Non-Executive)	30,000	-
			Independent Director	15,000	15,000
Audit Committee			Audit Committee		
Chairman and Director	-	-	Chairman	-	15,000
			Director	-	12,000
Nomination and Remuneration Committee			Nomination and Remuneration Committee		
Chairman and Director	-	-	Chairman	-	15,000
			Director	-	12,000

2025			2026 (Propose)		
Committee / Position	Yearly Remuneration	Meeting Allowance	Committee / Position	Monthly Remuneration	Meeting Allowance
	(Baht/Year)	(Baht/Time)		(Baht/Month)	(Baht/Time)
Corporate Governance and Sustainability Committee			Corporate Governance and Sustainability Committee		
Chairman and Director	-	-	Chairman	-	15,000
			Director	-	12,000
Risk Management and Investment Committee			Risk Management and Investment Committee		
Chairman and Director	-	-	Chairman	-	15,000
			Director	-	12,000
Group Executive Committee			Group Executive Committee		
Chairman and Director	-	-	Chairman and Director	70,000	-

3. Other remunerations In the form of awards, gratuities, bonuses, or other compensation payable in the year 2026, in an amount not exceeding THB 40,000,000 with the Chairman of the Board authorized to determine the criteria and approve the allocation.

Non-Monetary Remuneration

- None -

The Board of Directors' Opinion: The Board of Directors has jointly considered the recommendation of the Nomination and Remuneration Committee, which conducted a survey of directors' and subcommittee members' remuneration for the year 2026, taking into account the Company's performance, as well as the responsibilities and performance of the Board of Directors. Accordingly, the Board deems it appropriate to propose that the shareholders' meeting approve the directors' remuneration for the year 2026, comprising (1) monthly remuneration, (2) meeting allowances, and (3) other remunerations, with no non-monetary benefits.

Required Votes: This agenda requires the majority vote of shareholders attending the meeting and casting their votes.

Agenda 7: To ratify the audit fee for 2025

Objective and Rationale: As approved by the 2025 Annual General Meeting of Shareholders, the audit fee for the year 2025 was set at Baht 1,935,000. However, the actual expenses incurred amounted to Baht 2,185,000. This increase was due to an expansion of the audit scope following the consolidation of Thonburi Healthcare Group Public Company Limited (THG) from August 1, 2025, and Chiangmai Ram Hospital Co., Ltd. (CMH) from December 1, 2025, resulting in the audit fee exceeding the initially approved amount.

Audit Committee's Opinion: The Audit Committee has considered and is of the opinion that the increase in the audit fee for the year 2025 is appropriate and commensurate with the expanded scope and volume of audit work, resulting from the additional consolidation of subsidiaries. This has led to greater complexity in the audit process and requires increased specialized expertise.

The Board of Directors' Opinion: The Board of Directors has considered and concurred with the recommendation of the Audit Committee that the increase in the audit fee for the year 2025 is appropriate and reasonable, in line with the expanded scope of audit work resulting from the additional consolidation of subsidiaries.

The Board is of the view that such remuneration is appropriate in view of the nature, size, and increasing complexity of the Company's business. It is also necessary to ensure that the audit is conducted in full compliance with the relevant standards. Accordingly, the Board deems it appropriate to propose that the 2026 Annual General Meeting of Shareholders consider and ratify the audit fee for the year 2025.

Required Votes: This agenda requires the majority vote of shareholders attending the meeting and casting their votes.

Agenda 8: To consider and approve the appointment of auditor and the audit fee for 2026

Objective and Rationale: In accordance with the Public Limited Companies Act B.E. 2535, as amended which prescribes that at annual general meeting of shareholders shall appoint the auditor and determine the audit fee every year;

Audit Committee’s Opinion: The Audit Committee has considered that auditors from Dharmniti Auditing Company Limited have all the qualifications as specified by the Securities and Exchange Commission (hereinafter referred to as “SEC”) and perform their duties appropriately, as well as such audit company is reliable and is widely accepted and audit fee appropriate for the amount of work. Therefore, it is appropriate to propose appointing the auditors from the Dharmniti Auditing Company Limited for the Company, subsidiaries and associated companies of the Company for 2026.

The Board of Directors’ Opinion: The Board of Directors has considered and approved recommendation of the Audit Committee. Therefore, it is deemed appropriate to propose to the 2026 AGM to consider and approve the appointment of auditor and the audit fee for the year 2026, as follows:

1) To appoint Dharmniti Auditing Company Limited as the company's auditor, subsidiaries and associated companies of the Company for 2026, with one of their auditors to conduct the audit and certify the company's financial statements for the year 2026, or another auditor approved by the Securities and Exchange Commission (SEC). The company designates the following auditors to be responsible for the company's financial statements:

Name-Surname	Certified Public Accountant No.	Number of years as the Company’s auditor
1. Miss Methavee Chanasonkram	12784	2023 - 2025
2. Miss Naralee Karnsonth	14205	-
3. Mr. Vorakorn Sangpo	14409	-
4. Miss Arisa Chumwisut	9393	-

The aforementioned audit company and 4 auditors have no relationship or conflict of interest with the Company, directors, executives or major shareholders of the Company or those related to the people mentioned above.

2) To approve the audit fee for 2026 in the amount of 2,135,000 baht (divided into the audit fee for 3 quarters equal to 975,000 baht and the annual equal to 1,160,000 baht).

(Unit: Baht)

Audit Fee	2025	2026 (Proposed)
1) Audit fee for the Annual Consolidated the Separate Financial Statements	1,035,000	1,160,000
2) Audit fee for 3 quarters	900,000	975,000
3) Non-audit fee	None	None
Total	1,935,000	2,135,000

Note: Excluding out-of-pocket expenses incurred in the course of the audit, which will be charged on an actual basis, not exceeding 10% of the annual audit fee.

Most of the subsidiaries are audited by the same auditor, Dharmniti Auditing Co., Ltd. In cases where certain subsidiaries are audited by other auditors, the Board of Directors will ensure that their financial statements can be prepared and completed within the prescribed timeframe.

3) To consider and approve the allocation of a reserve amount for additional review/related services (if any) of not exceeding 10% of the auditors' remuneration approved by the Shareholders' Meeting for the year 2026, and to authorize the Board of Directors to approve the utilization of such amount as necessary and appropriate.

Required Votes: This agenda requires the majority vote of shareholders attending the meeting and casting their votes.

Agenda 9: To consider other matters (if any)

The Company provided shareholders with the opportunity to propose agenda for consideration during the period from 30 September 2025 to 31 December 2025, it appears that no shareholder submitted any agenda for consideration.

In order to allow shareholders to participate in making decisions on important matters, it is deemed inappropriate to add agenda without prior notice. Therefore, the meeting will be conducted in accordance with the agenda specified in this Notice of the Shareholders' Meeting, in compliance with the Corporate Governance Code and the Annual General Shareholders' Meeting Assessment.

For convenience, if any shareholder is unable to attend the meeting in person and wishes to appoint a proxy to attend and vote on his/her behalf, please complete and sign the proxy form (Form A, Form B, or Form C—Form C is applicable only for foreign investors appointing a custodian in Thailand) as provided in *Enclosure 10*, or download it from the Company's website at <https://investor.ram-hosp.co.th/th/shareholder-information/shareholders-meeting> (only one form may be used).

Shareholders may appoint a director of the Company as their proxy, as specified in *Enclosure 4* attached to this Notice. The completed and signed proxy form, together with supporting documents, should be sent by post to the Company Secretary Office, 5th Floor, Building 4, Ramkhamhaeng Hospital Public Company Limited, 436 Ramkhamhaeng Road, Hua Mak, Bang Kapi, Bangkok 10240.

The Company kindly requests shareholders to review and comply with the guidelines for attending the meeting and the required documents as specified in *Enclosure 3*. Please present the required documents and evidence of shareholding or proxy authorization at the meeting venue prior to the meeting. For convenience in registration, please also bring the meeting registration form for identity verification.

The Company has published the Notice of the 2026 Annual General Meeting of Shareholders and all supporting documents, which are identical to those delivered to shareholders, on the Company's website at www.ram-hosp.co.th under the Investor Relations section from March 30, 2026 onwards. Should any shareholder wish to receive a hard copy of

the proxy form, please contact the Company via email at Officeceo@ram-hosp.com or telephone at +66 2 743 9999 ext. 4505.

The Company cordially invites all shareholders to attend the meeting in person or appoint a proxy to attend the meeting on their behalf at the date, time, and venue specified above.

Yours sincerely,

- Signature -

(Dr. Pitchaya Somburanasin, M.D.)

Chairman of the Board of Directors

- Translation -

**Minutes of the 1/2025 Extraordinary General Meeting of Shareholders of
Ramkhamhaeng Hospital Public Company Limited**

The meeting was held on Tuesday, June 10, 2025, at 10.00 A.M., at the meeting room on the 10th floor, Building 3, Ramkhamhaeng Hospital Public Company Limited, No. 436 Ramkhamhaeng Road, Hua Mak, Bangkok, Bangkok 10240.

The Company has set April 24, 2025, as the record date for determining the list of shareholders entitled to attend the 1/2025 Extraordinary General Meeting of Shareholders, there were 4,276 shareholders, representing a total of 1,200,000,000 shares.

Meeting Quorum

Miss Chanyawat Watthanaphongsaphat, the Company Secretary, informed the meeting that the 1/2025 Extraordinary General Meeting of Shareholders of Ramkhamhaeng Hospital Public Company Limited (“**the Company**” or “**RAM**”) was attended by 20 shareholders in person, representing 111,457,811 shares, and by 59 proxies, representing 874,727,955 shares. In total, there were 79 shareholders attending the meeting, representing 986,185,766 shares, which constitutes 82.1821 percent of the total issued shares of the Company, thus constituting a quorum in accordance with the Company’s Articles of Association.

The Company Secretary then introduced the directors, executives, financial advisors, and legal advisors present at the meeting as follows:

Directors attending the Meeting in person

1. Dr. Pitchaya Somburanasin, M.D. Chairman of the Board of Directors, Chairman of Group Executive Committee and Member of the Risk Management and Investment Committee
2. Dr. Rukkagee Kanjanapitak (PH.D.) Director, Member of Group Executive Committee, Member of the Risk Management and Investment Committee, Member of the Nomination and Remuneration Committee and Group Chief Executive Officer

3. Dr. Suthee Leelasetakul, M.D. Director, Member of Group Executive Committee and Chief Executive Officer of Ramkhamhaeng Hospital
4. Dr. Jernpol Bhumitrakul, DDS. Director, Member of Group Executive Committee, Group Chief Operating Officer and Chief Affiliate Hospital Group 1
5. Dr. Siripong Luengvarinkul, M.D. Director, Member of Group Executive Committee and Chief Affiliate Hospital Group 2
6. Mr. Talit Chuen-Im Director, Member of Group Executive Committee, Member of the Risk Management and Investment Committee and Executive Vice President, Northeastern Hospital Group
7. Miss Tassawan Sirivongs Director
8. Mr. Benny Lim Director, Member of the Risk Management and Investment Committee and Member of the Nomination and Remuneration Committee
9. Mr. Pramol Apirat Independent Director and Chariman of Audit Committee
10. Miss Kittiyarat Jirojdamrongchai Independent Director and Member of Audit Committee
11. Mr. Kajit Habanananda Independent Director, Member of Audit Committee and Member of the Nomination and Remuneration Committee
12. Dr. Somsri Pausawasdi (M.D.) Independent Director and Member of the Nomination and Remuneration Committee

Directors attending the Meeting via electronic media

1. Dr. Pinit Hirunyachote, M.D. Independent Director and Member of the Nomination and Remuneration Committee
2. Miss Cheryl Ang Yan Qi Director

A total of 14 directors of the Company attended the meeting out of all 15 directors, representing 93.33 percent of the total number of directors.

Executive attending the Meeting in person

1. Dr. Pramuk Unachak (M.D.) Member of Group Executive Committee and Executive Vice President, Northern Hospital Group
2. Mr. Surabot Visutimatakul Chief Financial Officer

Financial Advisor attending the Meeting in person

1. Mr. Disapong Jaipakdeemun D Capital Advisory Co., Ltd.
2. Miss Kanyarat Kanaprach D Capital Advisory Co., Ltd.

Legal Advisor attending the Meeting in person

1. Miss Pornpan Chayasuntorn Linklaters (Thailand) Ltd.
2. Mr. Paveen Khiewwichit Linklaters (Thailand) Ltd.

The Company invited legal advisors from Linklaters (Thailand) Limited to act as witnesses for the vote counting process at this meeting.

OJ International Co., Ltd. was an inspection for the registration and voting system for this meeting.

Preliminary Proceeding before the Meeting

Before proceeding with the agenda items, the Company Secretary informed the meeting that the Company would collect, use, and disclose the personal data of all attendees by recording photographs and video for the purposes of recording and preparing the minutes of the meeting, as well as for managing the meeting. The Company Secretary then explained the procedures and guidelines for the meeting as follows:

1. The meeting will consider matters in accordance with the agendas in the invitation letter. Information will be presented for each agenda, and shareholders will be given the opportunity to ask questions before voting. The voting results will be announced to the meeting once the vote counting for each agenda has been completed.
2. Voting Procedure

- 2.1 In casting votes, one (1) share shall have one (1) vote. Therefore, each shareholder shall have votes equal to the number of shares he/she hold or have been granted proxy authority for.
 - 2.2 For this meeting, there are a total of 2 agenda proposed for the shareholders' consideration. Agenda 1 require the majority vote of shareholders attending the meeting and casting their votes. Agenda 2 requires approval by not less than three-fourths (3/4) of the total votes of the shareholders who attend the meeting and are entitled to vote. Agenda 3 is for other matters; the Company will allow shareholders to ask questions or express opinions as appropriate.
 - 2.3 In casting votes, the Company will collect ballot cards only from shareholders who vote "disapprove" or "abstain." For each agenda, the meeting will be asked whether there are any votes of disapproval or abstention. If there are, shareholders or proxy holders are requested to submit their completed and signed ballot cards to the Company's staff.
 - 2.4 In vote-counting, the Company will deduct the number of votes marked as "disapprove" and "abstain" from the total number of votes of shareholders present or casting votes. The remaining votes will be considered as votes "Approve"
3. Questioning and Commenting Procedure
 - 3.1 Before voting on each agenda, shareholders will be given the opportunity to ask questions or express opinions related to that agenda, as appropriate. The Company will provide responses to relevant questions during the discussion of the corresponding agenda. However, in the event of a large number of questions, the Company reserves the right to select questions as deemed appropriate. Some questions may be addressed at the end of the meeting or published on the Company's website.
 - 3.2 For shareholders who granted proxies to others to attend the meeting and selected the proxy form specifying their voting, the Company has already recorded their votes—whether in approve, disapprove, or abstained—according to their instructions in the registration system for use in the resolution of each agenda.
 - 3.3 Once the voting is closed, the Company will process the results and announce the vote result to the meeting for each agenda.

4. The Company will publish the meeting minutes in both Thai and English on the Company's website, and will notify the publication of the meeting minutes through the Information Disclosure System of the Stock Exchange of Thailand within 14 days from the date of the meeting.

Commencement of the Meeting

Dr. Pitchaya Somburanasin, Chairman of the Board of Directors, served as the Chairman of the Meeting ("**the Chairman**"). He welcomed the shareholders and appointed Miss Chanyawat Watthanaphongsaphat, the Company Secretary, to serve as the Secretary of the Meeting ("**the Secretary**"). The Chairman then proposed that the meeting consider the matters in accordance with the agendas in the invitation to the shareholder meeting, as follows:"

Agenda 1 To consider and certify the minutes of meeting of the Annual General Meeting of Shareholders for the year 2025 on April 30, 2025

The Chairman assigned the Secretary to propose that the meeting certify the minute of meeting of the Annual General Meeting of Shareholders for the year 2025 on April 30, 2025 as follows:

the Company held the Annual General Meeting of Shareholders for the year 2025 on April 30, 2025, with the minutes of the meeting appearing in Enclosure 1 , in which the Company has published a copy of the said minutes of the meeting on the Company's website (<http://www.ram-hosp.co.th>) for shareholders to acknowledge and verify the correctness. The meeting minutes were sent to the Stock Exchange of Thailand and the Ministry of Commerce within the time frame specified by law.

The Board of Directors has considered that the minutes of the meeting have been recorded accurately and completely. Therefore, it is deemed appropriate to propose to the 1/2025 Extraordinary General Meeting of Shareholders to consider and certify the minutes of the meeting.

The Secretary gave shareholders the opportunity to ask questions regarding the minutes of meeting of Annual General Meeting of Shareholders for the year 2025 on April 30, 2025. There are no questions were raised.

The Secretary proposed that the meeting consider and certify the minute of meeting of the Annual General Meeting of Shareholders for the year 2025 on April 30, 2025. This agenda requires the majority vote of shareholders attending the meeting and casting their votes.

Resolution: The meeting resolved to certify the minute of meeting of the Annual General Meeting of Shareholders for the year 2025 on April 30, 2025, with the following votes:

Shareholders entitled to vote	Number of votes (shares)	Percentage
Approved	986,487,866	100.0000
Disapproved	0	0.0000
Abstained	0	0.0000
Voided Ballot	0	0.0000
	986,487,866	100.0000

Agenda 2 To consider and approve additional investment in Thonburi Healthcare Group Public Company Limited’s ordinary shares which may be deemed as an acquisition of the business of another company as the Company’s own

The Chairman assigned Mr. Disapong Jaipakdeemun (Financial advisor) to propose the shareholders to consider and approve the additional investment in Thonburi Healthcare Group Public Company Limited’s ordinary shares which may be deemed as an acquisition of the business of another company as the Company’s own as follows:

In additional investment in Thonburi Healthcare Group Public Company Limited’s ordinary shares is in-line with the Company’s strategic growth plan, to become one of Thailand’s leading private hospital groups, through strengthening treatment capabilities, expanding the patient base, and generating long-term sustainable revenue and profits for the Company’s shareholders. This includes investing in hospital groups with high potential, advanced medical capabilities, and a strong nationwide network. The hospital locations of the Company and Thonburi Healthcare Group Public Company Limited (“THG”) do not overlap and there is no direct competition in terms of geographical medical service coverage, while the patient base have a broad range including self-pay patients, patients under the Social Security scheme, patients under the National Health Security Office and international patients (medical tourism).

The Company will acquire the newly issued ordinary shares of THG offered exclusively to the Company through a private placement, totaling 430,500,000 shares, with a par value of THB 1.00 per share, at an offering price of THB 8.65 per share, amounting to a total value of THB 3,723,825,000 (the “Acquisition of THG’s PP Shares”). Currently, the Company holds 208,378,474 shares in THG, representing 24.59% of THG’s total issued and paid-up shares. After the completion of the Acquisition of THG’s PP Shares, the Company will hold 638,878,474 shares in THG, representing 49.99% of THG’s total issued and paid-up shares (after the registration of the capital increase for the newly issued ordinary shares offered through the private placement).

Following the completion of the Acquisition of THG’s PP Shares, the Company’s shareholding in THG will increase from 24.59% to 49.99% of THG’s total issued and paid-up shares (after the registration of the paid-up capital increase for the newly issued ordinary shares of THG offered through the private placement). As a result, the Company will acquire additional ordinary shares in THG, crossing the 25.00% threshold of the total voting rights of THG, which triggers an obligation to make a mandatory tender offer for all securities of THG pursuant to the Notification of the Capital Market Supervisory Board No. TorChor. 12/2554 Re: Rules, Conditions and Procedures for the Acquisition of Securities for Business Takeovers, dated 13 May 2011 (as amended) (“Notification TorChor. 12/2554”).

However, the Company intends to apply for a waiver of such mandatory tender offer obligation resulting from the Acquisition of THG’s PP Shares by virtue of a resolution of the shareholders’ meeting of the business (Whitewash) from the Office of the Securities and Exchange Commission (“SEC”) in accordance with the Notification of the Office of the Securities and Exchange Commission No. SorKor. 29/2561 Re: Rules for Requesting a Waiver from the Requirement to Make a Tender Offer for All Securities of the Business by Virtue of a Resolution of the Shareholders’ Meeting of the Business, dated 30 May 2018 (as amended) (“Notification SorKor. 29/2561”) (the “Whitewash Waiver”).

Following the Company’s receipt of the Whitewash Waiver from the SEC and the completion of the Acquisition of THG’s PP Shares, resulting in the Company holding 49.99% of THG’s total issued and paid-up shares (after the registration of the capital increase for the newly issued ordinary shares offered through the private placement), THG will proceed with offering newly issued ordinary shares to its existing shareholders in proportion to their respective shareholdings (Rights Offering), totaling 511,186,960 shares, with a par value of

THB 1.00 per share. The allocation ratio will be 5 existing ordinary shares to 2 newly issued ordinary shares (calculated based on the total number of shares after the registration of the capital increase for the newly issued shares offered through the private placement), at an offering price of THB 5.00 per share. The Company will exercise its rights to subscribe for the newly issued ordinary shares in proportion to its shareholding in THG to maintain its ownership percentage, and the Company will not exercise the right to oversubscribe for the newly issued ordinary shares (“Subscription of THG’s RO Shares”).

If other shareholders of THG fully exercise their rights to subscribe for the newly issued ordinary shares offered to existing shareholders in proportion to their respective shareholdings (Rights Offering), the Company’s shareholding in THG will remain at 49.99% of the total voting rights of THG after the registration of the paid-up capital increase for the newly issued ordinary shares offered through the Rights Offering. Conversely, if no other shareholders of THG exercise their rights to subscribe for the newly issued ordinary shares offered through the Rights Offering, the Company’s shareholding in THG may increase to a maximum of 58.33% of the total voting rights of THG after the registration of the capital increase for such shares. In such a case, the Company will not be obligated to make a mandatory tender offer for all securities of THG, as the transaction qualifies for an exemption under the rules prescribed in Notification TorChor. 12/2554. Furthermore, at present, the Company has no intention of acquiring any additional shares in THG following the subscription of the newly issued ordinary shares under the Rights Offering that would result in the Company being required to make a mandatory tender offer for all securities of THG under the criteria set forth in Notification TorChor. 12/2554.

The Company intends to finance the Acquisition of THG’s PP Shares and the Subscription of THG’s RO Shares entirely through borrowings from local financial institutions and has a plan for the loan repayment. However, the borrowings for this additional investment in THG may potentially, at certain points in time, cause the Company to be temporarily non-compliant with some financial covenants under existing loan agreements with other financial institutions. To prevent any potential breach of such financial covenants in the future, the Company has proactively submitted waiver requests for such financial covenant requirements to the relevant financial institutions and expects to obtain the necessary waivers prior to entering into the transaction.

Regardless of whether the Company holds 49.99% (in the event that all other THG shareholders fully subscribe to the Rights Offering) or 58.33% (in the event that no other THG shareholders subscribe to the Rights Offering) of the total voting rights in THG after the registration of the paid-up capital increase for the newly issued ordinary shares offered through the Rights Offering, THG will be considered a subsidiary of the Company. Accordingly, the Company will be required to prepare consolidated financial statements in accordance with the relevant accounting standards, starting from the date THG becomes a subsidiary of the Company, which will be after the completion of the capital increase. THG will use the proceeds from the capital increase for loan repayments and as working capital as specified, which will enhance THG's financial position, reduce its interest expense, lower its debt-to-equity ratio, and ultimately result in improving consolidated financial performance for the Company.

To ensure flexibility and efficiency in carrying out the necessary actions relating to the Additional Investment in the newly issued ordinary shares of THG as proposed above, it is proposed that the shareholders' meeting consider and approve the authorization of the Company's Board of Directors, or any person authorized by the Board of Directors, to be empowered to take all actions relating to the Acquisition of THG's PP Shares, the Whitewash Waiver application, and the Subscription of THG's RO Shares. Such authority should include, but not be limited to, the following:

(a) To negotiate, agree, amend, modify, finalize, and complete the terms and conditions as well as any other details relating to the Acquisition of THG's PP Shares, the Whitewash Waiver application, and the Subscription of THG's RO Shares, including any related transactions (such as financing arrangements and/or borrowing or providing guarantees);

(b) To negotiate, agree, amend, modify, execute, certify, finalize, and deliver contracts, notices, consents, waivers, or any other documents related to the Acquisition of THG's PP Shares, the Whitewash Waiver application, and the Subscription of THG's RO Shares, including any related transactions (such as documents concerning financing arrangements and/or borrowing or providing guarantees); and/or

(c) To perform any acts and execute any documents as necessary or deemed appropriate to ensure the completion of the Acquisition of THG's PP Shares, the Whitewash

Waiver application, and the Subscription of THG's RO Shares, including any other related transactions.

The Board of Directors' Opinion:

With respect to the acquisition of THG's newly issued ordinary shares offered through a private placement, the Board of Directors has considered and deemed that the price, value, and terms and conditions under the share subscription agreement between the Company and THG are appropriate. Following the receipt of the Whitewash Waiver from the SEC and the completion of the acquisition of THG's PP Shares, the Company will hold 49.99% of THG's total issued and paid-up shares. The use of proceeds from the capital increase has been specified for the repayment of existing loan obligations of THG and/or its subsidiaries, which will result in an improved financial position for THG. Such an improvement is expected to benefit the Company, as a shareholder of THG, through an appropriate return on investment in the form of dividends.

With respect to the subscription of newly issued ordinary shares of THG offered to existing shareholders in proportion to their shareholding (Rights Offering), the Board of Directors of the Company considers the subscription price and value of the RO Shares to be fair and equitable to all shareholders of THG. THG may receive capital increase proceeds from other shareholders, which would provide sufficient funds for loan repayments and working capital to THG. This will help further strengthen THG's financial position, which will ultimately benefit the Company as a shareholder of THG in the long term.

Regarding the corporate governance of THG, which will become a subsidiary of the Company following the completion of the Additional Investment Transactions in THG, the Company currently has no plan to nominate any additional directors to THG's board of directors within the next 12 months, despite the fact that the number of THG directors nominated by the Company (3 out of a total of 18 directors) does not correspond to the Company's shareholding proportion in THG. The Company considers that the current board of directors of THG comprises individuals with the necessary qualifications, expertise, and experience appropriate for the management and operation of THG's business. In addition, the Company plans to propose that THG's Board of Directors consider establishing a Business Unit Executive Committee for each hospital within the THG group. This initiative aims to enhance operational efficiency, promote transparency, and support THG's board in overseeing, reviewing, and screening the performance and operations of each hospital in

accordance with good corporate governance principles. The Company's board of directors believes that this approach is consistent with the Company's corporate governance policy for its subsidiaries and will yield long-term benefits to the Company as a shareholder of THG.

As for the source of funds used for the Additional Investment Transactions in THG, which are entirely financed through borrowings from local financial institutions and for which the Company has already executed loan agreement, the Board of Directors of the Company has considered and views that the terms and conditions of such loan agreements are appropriate, and that the Company has the financial capability to comply with the loan covenants and to repay such borrowings accordingly.

Therefore, the Board of Directors has resolved to propose that the 1/2025 Extraordinary General Meeting of Shareholders consider and approve Additional Investment Transactions in THG, together with the relevant authorizations as described above.

The Secretary gave shareholders the opportunity to ask questions regarding additional investment in Thonburi Healthcare Group Public Company Limited's ordinary shares which may be deemed as an acquisition of the business of another company as the Company's own. There are additional comments or inquiries, which can be summarized as follows:

1. Mr. Wichian Panametha (Shareholder)

■ **Expansion through Brownfield investments**

Dr. Rukkagee Kanjanapitak explained that Brownfield investment refers to investing in existing hospital businesses that are already in operation, allowing the Company to recognize revenue and profit immediately. This differs from Greenfield investment, which involves constructing a new hospital from the ground up and requires time after opening to build a patient base and generate operating profit—for example, Ramkhamhaeng Hospital 2 or other Ramkhamhaeng affiliated hospitals in upcountry areas.

■ **Criteria for a Waiver from Mandatory Tender Offer (Whitewash)**

Mr. Disapong Jaipakdeemun explained that investing in a public company listed on the Stock Exchange of Thailand, if the acquisition of shares reaches a point that triggers a mandatory tender offer—specifically at 25%, 50%, or 75% (Trigger Points)—the Company is obligated to make a tender offer for all securities of that company. However, the Company may apply for a waiver

from the mandatory tender offer with the Securities and Exchange Commission (SEC) by obtaining a resolution from the shareholders' meeting of the target company (a "Whitewash") in accordance with Form 247-7. This requires the approval of not less than three-fourths (3/4) of the total votes of shareholders who attend the meeting and are entitled to vote, excluding the votes of the party requesting the waiver (RAM).

On June 9, 2025, the shareholders' meeting of Thonburi Healthcare Group Public Company Limited resolved to approve the waiver.

■ **Difference between Investment Proportions of 49.99% and 50.00%**

Mr. Disapong Jaipakdeemun explained that if the Company were to acquire more than 50.00% of the newly issued ordinary shares under a Private Placement (PP) of THG, the rules and conditions for a Whitewash waiver would become significantly more complicated. Therefore, the Company does not intend to proceed with an investment at such a level.

2. **Mrs. Kasina Srisa-an (Proxy from the Thai Investors Association)**

- **How will borrowing from financial institutions for this investment affect the Company's financial position? It is noted that this could result in a significantly higher debt-to-equity (D/E) ratio in the Company's financial statements.**

Dr. Rukkagee Kanjanapitak explained that the impact from borrowing 5,000 million baht for this investment may result in a significant increase in certain financial ratios. However, the Company has already negotiated and obtained waivers from the financial institutions regarding these matters.

■ **Loan repayment plan**

Dr. Rukkagee Kanjanapitak explained that the Company's Board of Directors has considered selling non-core assets as a source of funds for loan repayment. These may include the sale of listed securities to enhance the Company's liquidity (Available for Sale), a golf course, or certain hospital businesses. The Company believes it has the capability to comply with the loan agreement conditions and to repay both the principal and interest of the loan.

3. Miss Bussakorn Ngampasuthadon (Shareholder)

- **What is the significance and necessity of the additional investment in the ordinary shares of Thonburi Healthcare Group Public Company Limited (“THG”)?**

Dr. Rukkagee Kanjanapitak explained that long-term business growth cannot be assessed based solely on the past three years, as that period coincided with the COVID-19 pandemic, during which hospital businesses experienced unusually high performance.

Currently, the Company is the major shareholder of THG, holding 24.59% of its shares. The Company sees strong growth potential in THG’s business. However, the operating challenges faced by THG in 2024 did not stem from its hospital operations but from other factors, such as substantial investments in certain loss-making assets and the detection of suspicious transactions, which THG has already disclosed. Therefore, if the Company does not to proceed with further investment in THG, it could lead to liquidity problems for THG and, in turn, negatively affect the Company as its major shareholder.

Moreover, passing up this investment opportunity would mean missing the chance to invest in a business with solid potential. Thonburi Hospital 1, THG’s flagship hospital, has long been recognized for its reputable and quality healthcare services.

- **Will this investment result in the loss of opportunities to invest in other projects that may yield better returns?**

Dr. Rukkagee Kanjanapitak explained that over the past two years, the Company has been planning to make additional investments in hospital businesses both domestically and internationally. When comparing Greenfield investments (new construction projects) with Brownfield investments (acquiring existing hospitals that can generate immediate profits), the investment in THG is considered a Brownfield investment that can deliver immediate returns.

Moreover, this investment will strengthen the Company’s overall business, enhance its bargaining power in the procurement of medical equipment and supplies, and allow for greater influence in setting strategic business

directions. All of this is aimed at maximizing long-term returns for the Company's shareholders.

There were no further questions and comments from shareholders on this agenda. The Secretary proposed that the meeting consider and approve additional investment in Thonburi Healthcare Group Public Company Limited's ordinary shares which may be deemed as an acquisition of the business of another company as the Company's own. This agenda requires approval by not less than three-fourths (3/4) of the total votes of the shareholders who attend the meeting and are entitled to vote.

Resolution: The meeting resolved to approve additional investment in Thonburi Healthcare Group Public Company Limited's ordinary shares which may be deemed as an acquisition of the business of another company as the Company's own, with the following votes:

Shareholders entitled to vote	Number of votes (shares)	Percentage
Approved	986,513,586	100.0000
Disapproved	0	0.0000
Abstained	0	0.0000
Voided Ballot	0	0.0000
	986,513,586	100.0000

Agenda 3 Other Matters (if any)

There are no shareholders proposed any additional agenda, the Secretary gave shareholders the opportunity to ask further questions. There are additional comments or inquiries, which can be summarized as follows:

- 1. Anonymous shareholder**
 - Will the ongoing construction at the front of Ramkhamhaeng Hospital 2 (RAM 2) affect the operating results of RAM 2?**

Dr. Siripong Luengvarinkul explained that the construction is for the electric train, which may require RAM 2 to renovate the front construction area

accordingly. RAM 2 plans to enhance the frontage to make it more attractive and replace the hospital signage to improve visibility.

For RAM 2's operating performance, it has grown faster than expected. RAM 2 will officially open the 4-dimensional radiation therapy center, with the opening ceremony held on Friday, June 27, 2025.

2. Mr. Wichian Panametha (Shareholder)

■ **The parking design of RAM 1 and RAM 2**

Dr. Siripong Luengvarinkul explained that previous directors compared between constructing a parking building and purchasing land to build a parking lot. They concluded that investing in purchasing land to build a parking lot has a lower cost per parking space than constructing a parking building. Additionally, this increases the land's value for the future and provides opportunities for business expansion using the land held.

For RAM 1, the company is currently considering the construction a parking building and expanding service areas using the existing parking lot land.

No other matters were proposed for consideration. The Chairman then thanked the shareholders for attending the meeting and adjourned the meeting.


The meeting was adjourned at 11.30 A.M.

_____ - Signature - _____ Chairman of the meeting
(Dr. Pitchaya Somburanasin, M.D.)

_____ - Signature - _____ Company Secretary
(Miss Chanyawat Watthanaphongsaphat)

56-1 One Report for the year 2025

(Please download from the attached QR Code)



Guidelines and Required Documents for registration to attend the meeting

1. Registration

Registration will be open 2 hour prior to the start of meeting, and shareholders or proxies can register in advance to attend the meeting.

2. Required Documents for registration to attend the meeting

(1) Individual Shareholder

1.1 In case of attending in person: Certified copy of a valid document issued by the government agencies which appears the photo of the shareholder including national ID, driving license, passport

1.2 In case of appointing a proxy to attend the meeting:

(A) Proxy form, as attached with the invitation, which has been properly filled out with complete and accurate information, and signed by both the shareholder (grantor) and the proxy (recipient).

(B) Certified copy of a valid document of the shareholder issued by the government agencies as specified in 1.1, duly certified as a true copy by the shareholder (grantor).

(C) Certified copy of a document of a proxy holder issued by the government agencies as specified in 1.1.

(2) Juristic person incorporated in Thailand

2.1 In case of attending by authorized director(s):

(A) A valid document of the authorized director(s) issued by the government agencies as specified in 1.1.

(B) Certified copy of the company affidavit of the juristic person showing the details of the authorized director(s) and affixed with the company's seal (if any), showing that the representative attending the meeting is authorized to act on behalf of the juristic person shareholder.

2.2 In case of appointing a proxy to attend the meeting:

(A) Proxy form, as attached with the invitation, which has been properly filled out with complete and accurate information, and signed by both the shareholder (grantor) and the proxy (recipient).

(B) Certified copy of the company affidavit of the juristic person showing the details of the authorized director(s) and affixed with the company's seal (if any), showing that the authorized director(s) who signs the proxy form is authorized to act on behalf of the juristic person shareholder.

(C) Certified copy of a document of the authorized director(s) of the company issued by the government agencies as specified in 1.1.

(D) A valid document of a proxy holder issued by the government agencies as specified in 1.1.

(3) Foreign Juristic person incorporated abroad

Relevant documents as applicable in 1) and 2) with the following conditions:

(A) Documents issued by the government agencies representing a juristic person as a lawful juristic person in that country with the details of the juristic person including but not limited to authorized director, headquarter address

(B) In case of non-English language, the juristic person shall provide an English translation version certified by the authorized director(s)

(4) Foreign Juristic person incorporated abroad and provide a proxy to a Custodian in Thailand

4.1 Custodian documents

(A) Proxy Form C signed by the authorized persons from the grantor and proxy holder with 20-baht stamp

(B) A copy of the confirmation letter or business license showing that the proxy holder can act as the custodian

(C) A certified copy of company registration of the custodian signed by the authorized person of the custodian with the company affix (if any) and the proof of the authorized person's signatory as the authorized

(D) A copy of the valid Identification Card or Government Identification Card, or Passport (for non-Thai), or corporate document specified in 3 (a) certified as true and correct copy by the grantor

(E) A certified copy of the valid Government Identification Card of the authorized person of the custodian who is the proxy holder

4.2 Shareholder documents

(A) The power of attorney of such grantor authorizing the custodian

(B) A certified copy of the company registration of the shareholder signed by the authorized person with company's affix (if any) and the documents showing the authorized person is the authorized representative of the grantor

(C) A copy of the valid Identification Card or Government Identification Card, or Passport (for non-Thai), or corporate document specified in 3 (a) certified as true and correct copy by the grantor.

4.3 Valid document issued by the government for the proxyholder shall be certified true copy

In case of non-English language, the juristic person shall provide an English translation version certified by the authorized director(s)

3. Appointment of Proxy

If any shareholder wishes to obtain a hard copy of the proxy form, please contact the Company via email at Officeceo@ram-hosp.com or by telephone at +66 2 743 9999 ext. 4505.

For Shareholders who authorize one of the Company's Directors to attend and vote on his or her behalf, the Shareholders can send the proxy form together with the required documents to the Company by mail to the following address. The proxy form and required documents shall be delivered to the Company by April 29, 2026 at 12.00 p.m.

Address to send the proxy form:

Company Secretary Office, 5th Floor, building 4

Ramkhamhaeng Hospital Public Company Limited

436 Ramkhamhaeng Rd., Huamak Sub-district, Bangkapi District, Bangkok 10240

4. In counting of votes, resolutions shall be passed by votes as follows:

Agenda 1 and Agenda 3 to Agenda 8 require the approval of the meeting by a majority vote of shareholders attending the meeting and casting their votes.

Except for Agenda 2 Report on the Company's results of operations for the year 2025 is for acknowledgment; therefore, no voting is required.

Agenda 5 Election of directors who retired by rotation, with shareholders being able to vote for each director individually.

Information of Directors proposed by the Company as proxy of shareholders

1. Dr. Pitchaya Somburanasin, M.D.

Position Chairman of the Board of Directors, Chairman of Group Executive Committee and Member of the Risk Management and Investment Committee

Age 53 years

Address Ramkhamhaeng Hospital Public Company Limited
436 Ramkhamhaeng Rd, Hua Mak, Bang Kapi, Bangkok 10240

Relationships with family of director and executive director

- None

Other position that may cause conflict of interest

- None

Having interest/ non-interest om the agenda proposed at the shareholders' meeting

- Having interest in Agenda 6– To approve the directors' remuneration for the year 2026
- No special interest which is different from other directors in all agenda proposed at the 2026 Annual General Meeting of Shareholders

2. Dr. Somsri Pausawasdi, M.D.

Position Independent Director and Chairman of the Nomination and Remuneration Committee

Age 86 years

Address Ramkhamhaeng Hospital Public Company Limited
436 Ramkhamhaeng Rd, Hua Mak, Bang Kapi, Bangkok 10240

Relationships with family of director and executive director

- None

Other position that may cause conflict of interest

- None

Having interest/ non-interest om the agenda proposed at the shareholders' meeting

- Having interest in Agenda 6– To approve the directors' remuneration for the year 2026
- No special interest which is different from other directors in all agenda proposed at the 2026 Annual General Meeting of Shareholders

Information of the directors who retired by rotation



Dr. Rukkagee Kanjanapitak, PH.D.

Director, Member of the Nomination and Remuneration Committee, Member of the Risk Management and Investment Committee and Member of Executive Committee

Age: 44 years

Type of directors: Director

Date of Appointment: 22 November 2023

Term of office: 2 years 5 months

Shareholding in the Company: 4.35% (as of 30 December 2025)

Education/Training

- Ph.D. Knowledge Management, Kingston University, UK
- M.Sc. Business Research Development, Kingston University, UK
- MA. International Finance, Kingston University, UK
- Bachelor of Accountancy (First Class Honors), Chulalongkorn University
- Healthcare Change Management, Cornell University, US
- Executive Healthcare Leadership, Cornell University, US
- Director Certification Program (DCP), IOD
- Certificate Program in Medical Leadership, Class 1, King Prajadhipok’s Institute
- Certificate Program in Medical Law, Class 1, Medical Council of Thailand

Current Roles as Director/Executive and Work Experience

- **Other listed companies: 2**

2024 – Present:	Group Chief Executive Officer	Ramkhamhaeng Hospital PCL.
2024 – Present:	Member of Executive Committee, Member of the Nomination and Remuneration Committee, and	Thonburi Healthcare Group PCL.

	Member of the Risk Management Committee	
2023 – Present:	Director, Member of the Nomination and Remuneration Committee	Ramkhamhaeng Hospital PCL.
2021 – Present:	Member of Executive Committee, and Member of the Risk Management and Investment Committee	Ramkhamhaeng Hospital PCL.
2020 – Present:	Director	Vibhavadi Hospital PCL.
2019 – Present:	Director	Thonburi Healthcare Group PCL.
2023	Managing Director	Ramkhamhaeng Hospital PCL.
2021 - 2023	Deputy Director, Finance and Accounting Department	Ramkhamhaeng Hospital PCL.

● **Non-Listed Companies: 8**

2025 – Present:	Director	Ramkhamhaeng Chiang Mai Hospital Co., Ltd.
2025 – Present:	Director	Chiangmai Ram Hospital Co., Ltd.
2025 – Present:	Director	Nan-Ram Hospital Co., Ltd.
2025 – Present:	Director	Mahasarakham Ram Hospital Co., Ltd.
2023 – Present:	Director	Chaiyaphum Ram Hospital Co., Ltd.
2023 – Present:	Director	M.I. Calibration Co., Ltd.
2016 – Present:	Director	Ram Nakara Co., Ltd.
Present:	Director	S.C.C. Land Co., Ltd.

Other position that may cause conflict of interest: None

Relationships with family of director and executive director: None

Attendance in 2025: Board of Directors	11/11 (or 100%)
Nomination and Remuneration Committee	5/5 (or 100%)
Risk Management and Investment Committee	2/2 (or 100%)
Executive Committee	15/15 (or 100%)
Shareholders' meeting	2/2 (or 100%)

Nomination Criteria: The Nomination and Remuneration Committee “NRC” Meeting No. 2/2026, on March 11, 2026 has conducted the careful and diligent nomination process of qualified individuals, considering the qualifications required by law, the company's Articles of Association, and relevant requirements. Additionally, the process will consider the knowledge, capabilities, expertise, and experience suitable for the company’s business, as well as the overall diversity of the board's qualifications. The recommendations were then presented to the Board of Directors' meeting No. 2/2026, held on March 11, 2026, for consideration.

Nomination Rationale: The Board of Directors, excluding directors with conflict of interest in the agenda, has jointly and deliberately considered the qualifications of **Dr. Rukkagee Kanjanapitak** and deemed it appropriate to propose to the Annual General Meeting of Shareholders to consider and appoint her as the Director of the Company for another term as she possesses the qualifications of Directors as required by the relevant laws and in accordance with the prescribed qualifications of the Directors of the Company. She also has extensive knowledge and expertise in management, accounting, and finance, which will be beneficial to the Company’s business operations.



Dr. Suthee Leelasetakul, M.D.

Director and Member of Executive Committee

Age: 69 years

Type of directors: Director

Date of Appointment: 28 April 2000

Term of office: 26 years

Shareholding in the Company: 0.04% (as of 30 December 2025)

Education/Training

- Bachelor of Medicine, Faculty of Medicine Siriraj Hospital, Mahidol University
- Internal Medicine Specialist, Ramathibodi Hospital, Mahidol University
- Director Accreditation Program (DAP), IOD

Current Roles as Director/Executive and Work Experience

- **Other listed companies: None**

2023 - Present Chief Executive Officer, Ramkhamhaeng Hospital, Ramkhamhaeng Hospital PCL.

1997 – Present Director, Ramkhamhaeng Hospital PCL.

1991 – Present Physician (Internal Medicine), Ramkhamhaeng Hospital

- **Non-Listed Companies: None**

Other position that may cause conflict of interest: None

Relationships with family of director and executive director: None

Attendance in 2025: Board of Directors	11/11 (or 100%)
Executive Committee	15/15 (or 100%)
Shareholders' meeting	2/2 (or 100%)

Nomination Criteria: The Nomination and Remuneration Committee “NRC” Meeting No. 2/2026, on March 11, 2026 has conducted the careful and diligent nomination process of qualified individuals, considering the qualifications required by law, the company's Articles of Association, and relevant requirements. Additionally, the process will consider the knowledge, capabilities, expertise, and experience suitable for the company’s business, as well as the overall diversity of

the board's qualifications. The recommendations were then presented to the Board of Directors' meeting No. 2/2026, held on March 11, 2026, for consideration.

Nomination Rationale: The Board of Directors, excluding directors with conflict of interest in the agenda, has jointly and deliberately considered the qualifications of **Dr. Suthee Leelasetakul** and deemed it appropriate to propose to the Annual General Meeting of Shareholders to consider and appoint him as the Director of the Company for another term as he possesses the qualifications of Directors as required by the relevant laws and in accordance with the prescribed qualifications of the Directors of the Company. He also has extensive knowledge and expertise in management, and medicine, which will be beneficial to the Company's business operations.

and relevant requirements. Additionally, the process will consider the knowledge, capabilities, expertise, and experience suitable for the company's business, as well as the overall diversity of the board's qualifications. The recommendations were then presented to the Board of Directors' meeting No. 2/2026, held on March 11, 2026, for consideration.

Nomination Rationale: The Board of Directors, excluding directors with conflict of interest in the agenda, has jointly and deliberately considered the qualifications of **Dr. Wiroj Onganunkun** and deemed it appropriate to propose to the Annual General Meeting of Shareholders to consider and appoint him as the Director of the Company for another term as he possesses the qualifications of Directors as required by the relevant laws and in accordance with the prescribed qualifications of the Directors of the Company. He also has extensive knowledge and expertise in management, and medicine, which will be beneficial to the Company's business operations.



Mr. Wacharalak Tunskul

Independent Director, Chairman of the Audit Committee and Member of Corporate Governance and Sustainability Committee ⁽²⁾

Age: 47 years

Type of directors: Independent Director ⁽¹⁾

Date of Appointment: 27 February 2026

Term of office: 2 months 3 days

Shareholding in the Company: None (as of 30 December 2025)

Education/Training

- Master of International Business / Business Administration, University of Wollongong, Australia
- Bachelor's Degree in Accounting, Kasetsart University

Current Roles as Director/Executive and Work Experience

- **Other listed companies:** None

2026 - Present Independent Director, Chairman of the Audit Committee and Member of Corporate Governance and Sustainability Committee Ramkhamhaeng Hospital PCL.

- **Non-Listed Companies: 1**

2010 – Present	Managing Director	KornThai Co., Ltd.
2007 – 2010	Financial Accountant	Valad Property Group, Australia
2007 – 2007	Accountant	Capax P/L, Sydney
2006 – 2007	Assistant Accountant	Redder 4 P/L, Sydney
2005 – 2006	Assistant Accountant	Kingstyle P/L, Sydney
2004 – 2005	Senior Auditor	Horwath (Thailand) Ltd
2003 – 2004	Senior Auditor	KPMG Phoomchai Audit Ltd
2001 – 2003	Junior Auditor	SGV Na-Thalang (an Arthur Andersen firm)

Other position that may cause conflict of interest: None

Relationships with family of director and executive director: None

Attendance in 2025: Board of Directors	0/0
Audit Committee	0/0
Shareholders' meeting	0/0

Nomination Criteria: The Nomination and Remuneration Committee “NRC” Meeting No. 2/2026, on March 11, 2026 has conducted the careful and diligent nomination process of qualified individuals, considering the qualifications required by law, the company's Articles of Association, and relevant requirements. Additionally, the process will consider the knowledge, capabilities, expertise, and experience suitable for the company’s business, as well as the overall diversity of the board's qualifications. The recommendations were then presented to the Board of Directors' meeting No. 2/2026, held on March 11, 2026, for consideration.

Relationship/Interest of Individual Nominated as Independent Director:

Being a close relative of other directors/ executives/ major shareholders/ controlling persons/ or persons to be nominated as directors/ executives or controlling persons of the Company or its subsidiaries	No
---	----

Having the following interests in the Company/ parent company/ subsidiaries/ affiliates or any legal entities that may have conflicts at present or in the past 2 years:

1. Being a director who participates in management, or being an employee, or advisor who receives a regular salary or fee	No
2. Being a professional service provider (e.g. auditor, lawyer or financial advisor)	No
3. Not currently a director appointed to represent the company’s directors, major shareholders, or the shareholder related to major shareholder.	No
4. Having the significant business relations that may affect the ability to perform duties independently	None

Nomination Rationale: Directors, excluding of directors with conflict of interest in the agenda, has jointly and deliberately considered the qualifications of **Mr. Wacharalak Tunskul** and deemed it appropriate to propose to the Annual General Meeting of Shareholders to consider and appoint him as the Independent Director of the Company for another term as he possesses the qualifications of Independent Directors as required by the relevant laws and in accordance with the prescribed qualifications of the Independent Directors of the Company. In addition, He is neither nominated by the Company’s major shareholders nor executives and can express him opinion independently. He also has extensive knowledge and expertise in accounting, which will be beneficial to the Company’s business operations.

- Note:**
1. Appointed to the position with effect from February 27, 2026, in replacement of a resigned director.
 2. The Corporate Governance and Sustainability Committee was established as a subcommittee on February 27, 2026; therefore, no meetings were held in 2025.



Miss Kittiyarat Jirojdamrongchai

Independent Director and Member of the Audit Committee

Age: 72 years

Type of directors: Independent Director

Date of Appointment: April 2008

Term of office: 18 years

Shareholding in the Company: None (as of 30 December 2025)

Education/Training

- Bachelor of Arts (Human Resources), Phranakon Rajabhat University
- Higher Diploma (Accounting), Chetuphon College Commerce
- Mini MBA, Kasetsart University

Current Roles as Director/Executive and Work Experience

- **Other listed companies: None**
2008 – Present Independent Director and Member of Audit Committee, Ramkhamhaeng Hospital PCL.
- **Non-Listed Companies: None**
1979 - 2016 Deputy Director of Business Systems Division, Business Development Department, Provincial Electricity Authority

Other position that may cause conflict of interest: None

Relationships with family of director and executive director: None

Attendance in 2025: Board of Directors	11/11 (or 100%)
Audit Committee	8/8 (or 100%)
Shareholders' meeting	2/2 (or 100%)

Nomination Criteria: The Nomination and Remuneration Committee “NRC” Meeting No. 2/2026, on March 11, 2026 has conducted the careful and diligent nomination process of qualified individuals, considering the qualifications required by law, the company's Articles of Association, and relevant requirements. Additionally, the process will consider the knowledge, capabilities, expertise, and experience suitable for the company's business, as well as the overall diversity of the board's qualifications. The recommendations were then presented to the Board of Directors' meeting No. 2/2026, held on March 11, 2026, for consideration.

Relationship/Interest of Individual Nominated as Independent Director:

Being a close relative of other directors/ executives/ major shareholders/ controlling persons/ or persons to be nominated as directors/ executives or controlling persons of the Company or its subsidiaries	No
---	----

Having the following interests in the Company/ parent company/ subsidiaries/ affiliates or any legal entities that may have conflicts at present or in the past 2 years:

1. Being a director who participates in management, or being an employee, or advisor who receives a regular salary or fee	No
2. Being a professional service provider (e.g. auditor, lawyer or financial advisor)	No
3. Not currently a director appointed to represent the company's directors, major shareholders, or the shareholder related to major shareholder.	No
4. Having the significant business relations that may affect the ability to perform duties independently	None

Nomination Rationale: Directors, excluding of directors with conflict of interest in the agenda, has jointly and deliberately considered the qualifications of **Miss Kittiyarat Jirojdamrongchai** and deemed it appropriate to propose to the Annual General Meeting of Shareholders to consider and appoint her as the Independent Director of the Company for another term as she possesses the qualifications of Independent Directors as required by the relevant laws and in accordance with the prescribed qualifications of the Independent Directors of the Company. In addition, she is neither nominated by the Company's major shareholders nor executives and can express her opinion independently. She also has extensive knowledge and expertise in accounting, which will be beneficial to the Company's business operations.

Notwithstanding that **Miss Kittiyarat Jirojdamrongchai** has served as an independent director for a period exceeding the prescribed term of nine years, the Board of Directors is of the opinion that she continues to perform her duties independently, provides valuable recommendations on an ongoing basis, and carries out her responsibilities in strict adherence to the principles of good corporate governance.

Information of the proposed auditors for the year 2026**1. Miss Methavee Chanasongkram**

SEC-approved auditor

Auditor Registration No. 12784

Name of Audit Firm Dharmniti Auditing Co., Ltd.

Education

- Bachelor of Business Administration (Accounting), Rajamangala University of Technology Thanyaburi

Experience

- Experience in external auditing more than 20 years
- Specialized in auditing financial statements across various industries, including: manufacturing, trading, healthcare, transportation and logistics, provident funds and mutual funds

Relationship with the Company No relationship with the Company, its directors, executives, major shareholders, or related persons

Tenure as the Company's Auditor 2023 – 2025 (3 years)

2. Miss Naralee Karnsonth

SEC-approved auditor

Auditor Registration No. 14205

Name of Audit Firm Dharmniti Auditing Co., Ltd.

Education

- Bachelor of Business Administration (Accounting), Rajamangala University of Technology Phra Nakhon

Experience

- Experience in external auditing more than 20 years
- Specialized in auditing financial statements across various industries, including: manufacturing, trading, healthcare and construction

Relationship with the Company No relationship with the Company, its directors, executives, major shareholders, or related persons

Tenure as the Company's Auditor Initial appointment

3. Mr. Vorakorn Sangpo

Auditor Registration No.	14409
Name of Audit Firm	Dharmniti Auditing Co., Ltd.
Education	<ul style="list-style-type: none"> ▪ Bachelor of Business Administration (Managerial Accounting), Kasetsart University
Experience	<ul style="list-style-type: none"> ▪ Experience in external auditing more than 11 years ▪ Specialized in auditing financial statements across various industries, including: manufacturing, trading, healthcare and construction
Relationship with the Company	No relationship with the Company, its directors, executives, major shareholders, or related persons
Tenure as the Company's Auditor	Initial appointment

4. Miss Arisa Chumwisut

SEC-approved auditor	
Auditor Registration No.	9393
Name of Audit Firm	Dharmniti Auditing Co., Ltd.
Education	<ul style="list-style-type: none"> ▪ Master of Accounting, Chulalongkorn University ▪ Bachelor of Business Administration (Accounting), Rajamangala University of Technology Thanyaburi
Experience	<ul style="list-style-type: none"> ▪ Experience in external auditing more than 20 years ▪ Specialized in auditing financial statements across various industries, including: manufacturing, trading, provident funds, mutual funds and government enterprise
Relationship with the Company	No relationship with the Company, its directors, executives, major shareholders, or related persons
Tenure as the Company's Auditor	Initial appointment



บริษัท โรงพยาบาลรามคำแหง จำกัด (มหาชน)
 ห้องประชุมชั้น 10 อาคาร 3
 436 ถนนรามคำแหง แขวงหัวหมาก เขตบางกะปิ กรุงเทพฯ 10240
 โทร 1512 หรือ 02-743-9999

Ramkhamhaeng Hospital Public Company Limited
 10th Floor Meeting Room, building 3
 436 Ramkhamhaeng Hospital, Ramkhamhaeng rd.,
 Huamak, Bangkok 10240
 Tel: 1512, 02-743-9999

Article of Association of Ramkhamhaeng Hospital Public Company Limited
in Relations to the Shareholders' Meeting

Chapter 5 Shareholder's Meeting

Article 29 The Board of Directors shall convene a shareholders' meeting as an annual general meeting within 4 months from the end of the fiscal year of the Company.

Meetings other than those stated above shall be called Extraordinary Meetings. The Board of Directors may call a shareholders' meeting as an extraordinary meeting whenever they deem appropriate, or when the shareholders' holding shares in the aggregate amounts not less than one-fifth of the total issued shares, or at least 25 shareholders holding shares in the aggregate amounts not less than one-tenth of the total issued shares have submitted a letter requesting the Board of Directors to call an Extraordinary General Meeting at any time. However, the reason for calling the meeting must be clearly stated in the aforementioned letter.

The Board of Directors shall convene the Shareholders' Meeting within 1 month from the date of the receipt of the letter.

Article 30 In convening a shareholders' meeting, the Board of Directors shall prepare a meeting invitation letter specifying the venue, date, time of the meeting, agenda and the matters to be proposed to the meeting together with appropriate details stating clearly whether they will be for acknowledgment, for approval or for consideration, as the case may be, including the opinions of the Board of Directors on the said matters and shall send the letter to the shareholders at least 7 days prior to the date of the meeting. Publication of the invitations of the meeting shall also be made in a newspaper for 3 consecutive days at least 3 days prior to the date of the meeting.

The Board of Directors shall fix the date, time and venue of the shareholders' meeting. The venue of the shareholders' meeting must be at the district where the head office or branch is located, or in the province near the location of the head office and branch, or in another province as the Board of Directors may deem appropriate.

Article 31 A quorum for a shareholders' meeting shall consist of not less than a total 25 shareholders or proxies (if any) or consist of not less than half of the total number of shareholders, holding not less than one-third of the total issued shares.

If after one hour from the meeting time set forth for the shareholders' meeting, the number of shareholders presence is insufficient to form a quorum as specified, if such shareholders' meeting was convened at the request of shareholders, it shall be cancelled. If such shareholders' meeting was not convened at the request of the shareholders, a new meeting shall be called again and the meeting invitation letter shall be sent to the shareholders not less than 7 days before the date of the meeting. In the later meeting, a quorum is not compulsory.

Article 32 In the shareholders' meeting, the shareholders may appoint another person of legal age to attend the meeting and vote on their behalf in the meeting. The instrument appointing proxy shall be dated and signed by the shareholder giving proxy and shall be in the form so prescribed by the registrar.

This instrument appointing proxy shall be submitted to the Chairman of the Board of Directors or a person entrusted by the Chairman at the meeting venue before the proxy attends the meeting.

Article 33 In casting votes, one share shall be entitled to one vote and the resolution of the shareholders' meeting shall comprise of the following votes:

- (1) In normal cases, a resolution shall be passed by the majority of votes of shareholders present at the meeting and exercising the voting rights. In case of a tie, the Chairman of the meeting shall have an additional vote as a casting vote;
- (2) In the following cases, a resolution shall be passed by votes of not less than three-fourths of the total number of votes of shareholders who attend the meeting and are entitled to vote:
 - A. The sell or transfer of the whole or substantial parts of the Company's business to other persons;
 - B. The purchase or acceptance of transfer of business of other companies

- or private companies to the Company;
- C. The entry, amendment, or termination of contracts relating to the leasing out of the whole or substantial parts of the Company's business, the assignment to any other persons to manage the Company's business or the consolidation of the business with other persons with an objective towards profit and loss sharing;
 - D. The amendment of the Memorandum of Association or the Articles of Association of the Company;
 - E. The capital increase, reduction, issuance of debentures, merger or dissolution.

Article 34 Transactions to be conducted at the Annual General Meeting are as follows:

- (1) Review the report of the Board of Directors covering the works performed during the preceding year as proposed to the meeting by the Board of Directors;
- (2) Consider and approve the Company's financial statements;
- (3) Appoint new directors in replacement of those retiring by rotation;
- (4) Appoint the auditors;
- (5) Other businesses

Data Privacy Notice

In order to comply with the Personal Data Protection Act B.E. 2562 (2019), the Company has implemented the following personal data protection measures:

1. Personal Data Collected

The Company will collect and process your personal data, whether provided directly by you to the Company or obtained from Thailand Securities Depository Co., Ltd. (TSD), in its capacity as the Company's securities registrar. Such data includes, but is not limited to, the following:

- General personal data, such as name-surname, date of birth, age, address, telephone number, facsimile number, email address, identification card number, passport number, nationality, shareholder registration number, number of shares held, class of shares, educational background, training records, and employment history.
- Financial information, for the purpose of processing shareholder benefits, such as bank account number, bank name, and cheque number.
- Photographs and video recordings from the shareholders' meeting, including computer traffic data generated from registration for the meeting and/or records during such meeting.
- Information provided via the Company's investor relations channels on its website or through other channels as designated by the Company.

The Company does not intend to collect or process any sensitive personal data, including your religious beliefs and blood type (if any), which may appear on identification documents submitted by you and/or your proxy to the Company. In the event that the Company receives such information by any means, the Company will mask such data on the documents and will not be deemed to have collected or processed such information in any manner.

2. Purposes of Collection, Processing, and Disclosure of Personal Data

The Company is required to collect and process your personal data for the following purposes:

- Conducting shareholders' meetings, including proposing agenda items and nominating candidates for consideration as directors of the Company.
- Arranging and managing the meeting process, including the delivery of meeting-related

documents, identity verification for meeting registration, vote counting and processing, preparation of minutes of the shareholders' meeting, and any other activities in connection with such meetings.

- Publishing the minutes of the shareholders' meeting or information from photographs and video recordings of the meeting on the Company's website.
- Processing dividend payments or other shareholder benefits.
- Organizing Company activities, including communication through investor relations channels or other channels designated by the Company.
- Compliance with legal obligations and/or cooperation with courts, governmental authorities, regulatory bodies, and law enforcement agencies.

In order to achieve the above purposes, the Company may disclose your personal data to the following third parties:

- Thailand Securities Depository Co., Ltd. (TSD)
- Banks or financial institutions
- Service providers to the Company, such as printing, document delivery, data storage, technology providers for shareholders' meetings, or other related services, as part of the Company's legal obligations to shareholders and/or proxies
- Professional service providers, such as legal advisors, medical professionals, and auditors
- General investors, where required by applicable laws or regulations
- Courts, governmental authorities, regulatory bodies, law enforcement agencies, or any other persons or juristic entities to whom the Company is required to disclose information in order to comply with laws, governmental orders, or contractual obligations for the benefit of the data subjects (e.g., the Ministry of Commerce, the Revenue Department, etc.)

The Company will collect, process, and disclose your personal data for the above purposes based on legal obligations, contractual necessity, the Company's legitimate interests, and/or your consent (as the case may be).

In the event that the Company is required to collect, process, and/or disclose your

personal data based on legal obligations, contractual necessity, or your consent (as the case may be), and you are unable to provide certain necessary personal data or consent, the Company may be unable to manage or perform its contractual obligations with you, including providing any benefits to which you may be entitled as a shareholder (if any).

3. Retention Period of Personal Data

The Company will retain your personal data in accordance with applicable laws and/or as necessary to fulfill the purposes described above. Upon expiration of such period, the Company will destroy or anonymize the data so that it can no longer be used to identify an individual.

4. Rights of Data Subjects

Under the criteria set forth in the Personal Data Protection Act B.E. 2562 (2019), data subjects have the following rights:

- To access and obtain a copy of their personal data, or to request disclosure of the source of such data
- To request the Company to ensure that their personal data is accurate, complete, and up to date
- To request the Company to transfer their personal data as permitted by law
- To give or withdraw consent
- To object to the collection, use, or disclosure of their personal data
- To request the Company to erase, destroy, or anonymize their personal data
- To lodge a complaint with the Personal Data Protection Committee Office in the event of non-compliance with personal data protection laws

In the event that you submit a request to exercise your rights, the Company will proceed in accordance with such request within the timeframe prescribed by law. However, the Company reserves the right to refuse such requests where permitted by law.

5. Contact Information

If you have any questions or require further information, and/or wish to exercise your rights as a data subject under Clause 4, you may contact the Company at:

Company Secretary Office, 5th Floor, Building 4
Ramkhamhaeng Hospital Public Company Limited
436 Ramkhamhaeng Road, Hua Mak, Bang Kapi, Bangkok 10240

The Company may amend or revise this Personal Data Protection Notice from time to time, with such changes to be published on the Company's website and/or in the notice of the shareholders' meeting and/or through the Stock Exchange of Thailand's disclosure channels, and/or in accordance with applicable legal requirements.

หนังสือมอบฉันทะแบบ ก.

PROXY FORM A

ดิอากกร แสคมปี 20 บาท

เขียน

Written at

วันที่เดือนพ.ศ.

Date Month Year

(1) ข้าพเจ้า สัญชาติ

I/We Nationality

อยู่บ้านเลขที่

Address

(2) เป็นผู้ถือหุ้นของบริษัท โรงพยาบาลรามคำแหง จำกัด (มหาชน)

Being a shareholder of Ramkhamhaeng Hospital Public Company Limited

โดยถือหุ้นจำนวนทั้งสิ้นรวมหุ้น และออกเสียงลงคะแนนได้เท่ากับเสียง ดังนี้

Holding a total number of shares and having total voting rights of Votes as follows:

หุ้นสามัญหุ้น ออกเสียงลงคะแนนได้เท่ากับเสียง

Ordinary shares shares having total voting right of Votes

หุ้นบุริมสิทธิ.....หุ้น ออกเสียงลงคะแนนได้เท่ากับเสียง

Preferred shares shares having total voting right of Votes

(3) ขอมอบฉันทะให้

Hereby appoint

1. ...นายแพทย์พิชญ สมบูรณ์สิน.....อายุ53.....ปี

Dr. Pitchaya Somburanasin, M.D. Age Years

อยู่บ้านเลขที่436.....ถนนรามคำแหง..... ตำบล/แขวง ...หัวหมาก.....

Residing at No Street Sub-district

อำเภอ/เขตบางกะปิ.....จังหวัดกรุงเทพฯ.....รหัสไปรษณีย์10240.....

District Province Post Code **OR**

2.แพทย์หญิงสมศรี เฝ้าสวัสดิ์..... อายุ86.....ปี
 Dr. Suthee Leelasetakul, M.D. Age Years
 อยู่บ้านเลขที่436.....ถนนรามคำแหง..... ตำบล/แขวง ...หัวหมาก.....
 Residing at No Street Sub-district
 อำเภอ/เขตบางกะปิ.....จังหวัดกรุงเทพฯ.....รหัสไปรษณีย์10240.....
 District Province Post Code OR

3. อายุปี
 Age Years
 อยู่บ้านเลขที่ ถนน ตำบล/แขวง
 Residing at No Street Sub-district
 อำเภอ/เขตจังหวัดรหัสไปรษณีย์
 District Province Post Code OR

4. อายุปี
 Age Years
 อยู่บ้านเลขที่ ถนน ตำบล/แขวง
 Residing at No Street Sub-district
 อำเภอ/เขตจังหวัดรหัสไปรษณีย์
 District Province Post Code

คนใดคนหนึ่งเพียงคนเดียวเป็นผู้แทนของข้าพเจ้าเพื่อเข้าร่วมประชุมและออกเสียงลงคะแนนแทนข้าพเจ้าในการประชุม
 สามัญผู้ถือหุ้นประจำปี 2569 ในวันที่ 30 เมษายน 2569 เวลา 13.00 น. ณ ห้องประชุมชั้น 10 อาคาร 3 บริษัท โรงพยาบาล
รามคำแหง จำกัด (มหาชน) เลขที่ 436 ถนนรามคำแหง แขวงหัวหมาก เขตบางกะปิ กรุงเทพมหานคร 10240 หรือจะพึงเลื่อนไป
 ในวัน เวลา และสถานที่อื่นด้วย

Only one of them as my/our proxy to attend and vote on my/our behalf at the Annual General
 Meeting of Shareholder for the year 2026 to be held on April 30, 2026 at 13.00 hrs. The meeting will be
conducted at Meeting Room 10th floor Building 3, Ramkhamhaeng Hospital Public Company Limited, No.
436 Ramkhamhaeng Road, Hua Mark sub-district, Bangkapi district, Bangkok 10240. or at any adjournment
 thereof to any other date, time and place.

กิจการใดที่ผู้รับมอบฉันทะกระทำไปในการประชุมนั้น ให้ถือเสมือนว่าข้าพเจ้าได้กระทำเองทุกประการ

For any act performed by the Proxy at the meeting, it shall be deemed as such acts had been done by me/us in all respects.

ลงชื่อ/Signature.....ผู้มอบฉันทะ/Proxy Grantor
(.....)

ลงชื่อ/Signature.....ผู้รับมอบฉันทะ/Proxy Holder
(.....)

ลงชื่อ/Signature.....ผู้รับมอบฉันทะ/Proxy Holder
(.....)

ลงชื่อ/Signature.....ผู้รับมอบฉันทะ/Proxy Holder
(.....)

หมายเหตุ : ผู้ถือหุ้นที่มอบฉันทะจะต้องมอบฉันทะให้ผู้รับมอบฉันทะเพียงรายเดียวเป็นผู้เข้าประชุมและออกเสียงลงคะแนน ไม่สามารถแบ่งแยกจำนวนหุ้นให้ผู้รับมอบฉันทะหลายคนเพื่อแยกการลงคะแนนเสียงได้

Remark: A Shareholder can appoint only one proxy to attend and vote on his/her behalf and may not split the number of shares to many proxies for splitting votes.

หนังสือมอบฉันทะแบบ ข.

Proxy Form B

ติดอากร
แสตมป์
20 บาท

เขียน

Written at

วันที่เดือนพ.ศ.

Date Month Year

(1) ข้าพเจ้าสัญชาติอยู่บ้านเลขที่ถนน
I/We Nationality No. Road
ตำบล/แขวงอำเภอ/เขตจังหวัดรหัสไปรษณีย์
Sub-district District Province Post Code

(2) เป็นผู้ถือหุ้นของบริษัท โรงพยาบาลรามคำแหง จำกัด (มหาชน) โดยถือหุ้นจำนวนทั้งสิ้นรวมหุ้น
Being a shareholder of Ramkhamhaeng Hospital Public Company Limited Holding a total number of shares
และออกเสียงลงคะแนนได้เท่ากับเสียง ดังนี้

and having total voting rights of

Votes as follows:

หุ้นสามัญหุ้น ออกเสียงลงคะแนนได้เท่ากับเสียง

Ordinary shares shares having total voting right of Votes

หุ้นบุริมสิทธิ.....หุ้น ออกเสียงลงคะแนนได้เท่ากับเสียง

Preferred shares shares having total voting right of Votes

(3) ขอมอบฉันทะให้

Hereby appoint

1. ...นายแพทย์พิชญ สมบูรณ์สิน.....อายุ53.....ปี

Dr. Pitchaya Somburanasin, M.D. Age Years

อยู่บ้านเลขที่436.....ถนนรามคำแหง..... ตำบล/แขวงหัวหมาก.....

Residing at No Street Sub-district

อำเภอ/เขตบางกะปิ.....จังหวัดกรุงเทพฯ.....รหัสไปรษณีย์10240.....

District Province Post Code **OR**

2. ...แพทย์หญิงสมศรี เผ่าสวัสดิ์อายุ86.....ปี

Dr. Suthee Leelasetakul, M.D. Age Years

อยู่บ้านเลขที่436.....ถนนรามคำแหง..... ตำบล/แขวงหัวหมาก.....

Residing at No Street Sub-district

อำเภอ/เขตบางกะปิ.....จังหวัดกรุงเทพฯ.....รหัสไปรษณีย์10240.....

District Province Post Code **OR**

3.อายุปี
Age Years

อยู่บ้านเลขที่ถนน ตำบล/แขวง

Residing at No Street Sub-district

อำเภอ/เขตจังหวัดรหัสไปรษณีย์

District Province Post Code **QR**

4.อายุปี
Age Years

อยู่บ้านเลขที่ถนน ตำบล/แขวง

Residing at No Street Sub-district

อำเภอ/เขตจังหวัดรหัสไปรษณีย์

District Province Post Code

คนใดคนหนึ่งเพียงคนเดียวเป็นผู้แทนของข้าพเจ้าเพื่อเข้าร่วมประชุมและออกเสียงลงคะแนนแทนข้าพเจ้าในการประชุมสามัญผู้ถือหุ้นประจำปี 2569 ในวันที่ 30 เมษายน 2569 เวลา 13.00 น. ณ ห้องประชุมชั้น 10 อาคาร 3 บริษัท โรงพยาบาลรามคำแหง จำกัด (มหาชน) เลขที่ 436 ถนนรามคำแหง แขวงหัวหมาก เขตบางกะปิ กรุงเทพมหานคร 10240 หรือจะพึงเลื่อนไปในวัน เวลา และสถานที่อื่นด้วย

Only one of them as my/our proxy to attend and vote on my/our behalf at the Annual General Meeting of Shareholder for the year 2026 to be held on April 30, 2026 at 13.00 hrs. The meeting will be conducted at Meeting Room 10th floor Building 3, Ramkhamhaeng Hospital Public Company Limited, No. 436 Ramkhamhaeng Road, Hua Mark sub-district, Bangkapi district, Bangkok 10240. or at any adjournment thereof to any other date, time and place.

(4) ข้าพเจ้าขอมอบฉันทะให้ผู้รับมอบฉันทะออกเสียงลงคะแนนแทนข้าพเจ้าในการประชุมครั้งนี้ ดังนี้

For any act performed by the Proxy at the meeting, it shall be deemed as such acts had been done by me/us in all respects as follow:

วาระที่ 1 พิจารณารับรองรายงานการประชุมวิสามัญผู้ถือหุ้น ครั้งที่ 1/2568 เมื่อวันที่ 10 มิถุนายน 2568
Agenda 1: To consider and certify the minutes of meeting of the Extraordinary General Meeting of Shareholders No. 1/2025 on June 10, 2025

(ก) ให้ผู้รับมอบฉันทะมีสิทธิพิจารณาและลงมติแทนข้าพเจ้าได้ทุกประการตามที่เห็นสมควร

(a) To grant my/our proxy to consider and vote on my/our behalf as he/she may deem appropriate in all respects.

(ข) ให้ผู้รับมอบฉันทะออกเสียงลงคะแนนตามความประสงค์ของข้าพเจ้าดังนี้

(b) To grant my/our proxy to vote at my/our desire as follows:

เห็นด้วย ไม่เห็นด้วย งดออกเสียง
 Approve Disapprove Abstain

วาระที่ 2 รับทราบรายงานผลการดำเนินงานประจำปี 2568

Agenda 2: To acknowledge the report on the results of operations for the year 2025

**วาระที่ 3 พิจารณออนุมัติงบการเงินสำหรับปี สิ้นสุด ณ วันที่ 31 ธันวาคม 2568 ซึ่งผ่านการตรวจสอบ
 โดยผู้สอบบัญชีรับอนุญาตแล้ว**

**Agenda 3: To consider and approve the Financial Statements for the year ended 31
 December 2025 which have been audited by an authorized auditor**

(ก) ให้ผู้รับมอบฉันทะมีสิทธิพิจารณาและลงมติแทนข้าพเจ้าได้ทุกประการตามที่เห็นสมควร

(a) To grant my/our proxy to consider and vote on my/our behalf as he/she may deem appropriate in all respects.

(ข) ให้ผู้รับมอบฉันทะออกเสียงลงคะแนนตามความประสงค์ของข้าพเจ้าดังนี้

(b) To grant my/our proxy to vote at my/our desire as follows:

เห็นด้วย ไม่เห็นด้วย งดออกเสียง
 Approve Disapprove Abstain

วาระที่ 4 พิจารณออนุมัติการจ่ายเงินปันผล ประจำปี 2568

Agenda 4: To consider and approve the dividend payment for the year 2025

(ก) ให้ผู้รับมอบฉันทะมีสิทธิพิจารณาและลงมติแทนข้าพเจ้าได้ทุกประการตามที่เห็นสมควร

(a) To grant my/our proxy to consider and vote on my/our behalf as he/she may deem appropriate in all respects.

(ข) ให้ผู้รับมอบฉันทะออกเสียงลงคะแนนตามความประสงค์ของข้าพเจ้าดังนี้

(b) To grant my/our proxy to vote at my/our desire as follows:

เห็นด้วย ไม่เห็นด้วย งดออกเสียง
 Approve Disapprove Abstain

วาระที่ 5 พิจารณออนุมัติเลือกตั้งกรรมการที่ออกจากตำแหน่งตามวาระ

Agenda 5: To consider and approve the election of directors who retired by rotation

(ก) ให้ผู้รับมอบฉันทะมีสิทธิพิจารณาและลงมติแทนข้าพเจ้าได้ทุกประการตามที่เห็นสมควร

(a) To grant my/our proxy to consider and vote on my/our behalf as he/she may deem appropriate in all respects.

(ข) ให้ผู้รับมอบฉันทะออกเสียงลงคะแนนตามความประสงค์ของข้าพเจ้าดังนี้

(b) To grant my/our proxy to vote at my/our desire as follows:

การแต่งตั้งกรรมการเป็นรายบุคคลดังนี้

The appointment of certain directors as follows:

1. ดร.รูกขจี กาญจนพิทักษ์

Dr. Rukkagee Kanjanapitak, PH.D.

เห็นด้วย

ไม่เห็นด้วย

งดออกเสียง

Approve

Disapprove

Abstain

2. นายแพทย์สุธี ลิละเศรษฐกุล

Dr. Suthee Leelasetakul, M.D.

เห็นด้วย

ไม่เห็นด้วย

งดออกเสียง

Approve

Disapprove

Abstain

3. นายแพทย์วิโรจน์ องค์กรนันต์คุณ

Dr. Wiroj Onganunkun, M.D.

เห็นด้วย

ไม่เห็นด้วย

งดออกเสียง

Approve

Disapprove

Abstain

4. นายวัชรลักษณ์ ตันท์สกุล

Mr. Wacharalak Tunskul

เห็นด้วย

ไม่เห็นด้วย

งดออกเสียง

Approve

Disapprove

Abstain

5. นางสาวกิตติญารัตน์ จิโรจดำรงชัย

Miss Kittiyarat Jirojdamrongchai

เห็นด้วย

ไม่เห็นด้วย

งดออกเสียง

Approve

Disapprove

Abstain

วาระที่ 6 พิจารณานุมัติค่าตอบแทนกรรมการ ประจำปี 2569

Agenda 6: To consider and approve the directors' remuneration for the year 2026

(ก) ให้ผู้รับมอบฉันทะมีสิทธิพิจารณาและลงมติแทนข้าพเจ้าได้ทุกประการตามที่เห็นสมควร

(a) To grant my/our proxy to consider and vote on my/our behalf as he/she may deem appropriate in all respects.

(ข) ให้ผู้รับมอบฉันทะออกเสียงลงคะแนนตามความประสงค์ของข้าพเจ้าดังนี้

(b) To grant my/our proxy to vote at my/our desire as follows:

เห็นด้วย
Approve

ไม่เห็นด้วย
Disapprove

งดออกเสียง
Abstain

วาระที่ 7 ให้สัตยาบันค่าตอบแทนผู้สอบบัญชี ประจำปี 2568

Agenda 7: To ratify the audit fee for 2025

(ก) ให้ผู้รับมอบฉันทะมีสิทธิพิจารณาและลงมติแทนข้าพเจ้าได้ทุกประการตามที่เห็นสมควร
(a) To grant my/our proxy to consider and vote on my/our behalf as he/she may deem appropriate in all respects.

(ข) ให้ผู้รับมอบฉันทะออกเสียงลงคะแนนตามความประสงค์ของข้าพเจ้าดังนี้
(b) To grant my/our proxy to vote at my/our desire as follows:

เห็นด้วย
Approve

ไม่เห็นด้วย
Disapprove

งดออกเสียง
Abstain

วาระที่ 8 พิจารณามติการแต่งตั้งผู้สอบบัญชีและกำหนดค่าตอบแทนผู้สอบบัญชี ประจำปี 2569

Agenda 8: To consider and approve the appointment of auditor and the audit fee for 2026

(ก) ให้ผู้รับมอบฉันทะมีสิทธิพิจารณาและลงมติแทนข้าพเจ้าได้ทุกประการตามที่เห็นสมควร
(a) To grant my/our proxy to consider and vote on my/our behalf as he/she may deem appropriate in all respects.

(ข) ให้ผู้รับมอบฉันทะออกเสียงลงคะแนนตามความประสงค์ของข้าพเจ้าดังนี้
(b) To grant my/our proxy to vote at my/our desire as follows:

เห็นด้วย
Approve

ไม่เห็นด้วย
Disapprove

งดออกเสียง
Abstain

วาระที่ 9 พิจารณาวาระอื่นๆ (ถ้ามี)

Agenda 9: To consider other matters (if any)

(ก) ให้ผู้รับมอบฉันทะมีสิทธิพิจารณาและลงมติแทนข้าพเจ้าได้ทุกประการตามที่เห็นสมควร
(a) To grant my/our proxy to consider and vote on my/our behalf as he/she may deem appropriate in all respects.

(ข) ให้ผู้รับมอบฉันทะออกเสียงลงคะแนนตามความประสงค์ของข้าพเจ้าดังนี้
(b) To grant my/our proxy to vote at my/our desire as follows:

เห็นด้วย
Approve

ไม่เห็นด้วย
Disapprove

งดออกเสียง
Abstain

(5) การลงคะแนนเสียงของผู้รับมอบฉันทะในวาระใดที่ไม่เป็นไปตามที่ระบุในหนังสือมอบฉันทะนี้ถือว่าการลงคะแนนไม่ถูกต้องและไม่ใช่เป็นการลงคะแนนเสียงของข้าพเจ้าในฐานะผู้ถือหุ้น

Voting of the proxy in any agenda that is not as specified in this Proxy Form shall be considered as invalid and shall not be my/our voting as a shareholder.

(6) ในกรณีที่ข้าพเจ้าไม่ได้ระบุความประสงค์ในการออกเสียงลงคะแนนในวาระใดไว้หรือระบุไว้ไม่ชัดเจนหรือในกรณีที่ประชุมมีการพิจารณาหรือลงมติในเรื่องใดนอกเหนือจากเรื่องที่ระบุไว้ข้างต้น รวมถึงกรณีที่มีการแก้ไขเปลี่ยนแปลงหรือเพิ่มเติมข้อเท็จจริงประการใด ให้ผู้รับมอบฉันทะมีสิทธิพิจารณาและลงมติแทนข้าพเจ้าได้ทุกประการตามที่เห็นสมควร

In case I/we have not specified my/our voting intention in any agenda or not clearly specified or in case the meeting considers or passes resolutions in any matters other than those specified above, including in case there is any amendment or addition of any fact, the proxy shall have the right to consider and vote on my/our behalf as he/she may deem appropriate in all respects.

กิจการใดที่ผู้รับมอบฉันทะได้กระทำไปในการประชุม เว้นแต่กรณีที่ผู้รับมอบฉันทะไม่ออกเสียงตามที่ข้าพเจ้าระบุในหนังสือมอบฉันทะให้ถือเสมือนว่าข้าพเจ้าได้กระทำเองทุกประการ

Any business carried out by the proxy at the said meeting, except in case that the proxy does not vote according to my/our intention(s) specified in the Proxy Form, shall be deemed as having been carried out by myself/ourselves in all respects.

ลงชื่อ.....ผู้มอบฉันทะ
Sign Grantor
(.....)

ลงชื่อ.....ผู้รับมอบฉันทะ
Sign Proxy
(.....)

ลงชื่อ.....ผู้รับมอบฉันทะ
Sign Proxy
(.....)

ลงชื่อ.....ผู้รับมอบฉันทะ
Sign Proxy
(.....)

หมายเหตุ :

1. ผู้ถือหุ้นที่มีมอบฉันทะจะต้องมอบฉันทะให้ผู้รับมอบฉันทะเพียงรายเดียวเป็นผู้เข้าประชุมและออกเสียงลงคะแนน
ไม่สามารถแบ่งแยกจำนวนหุ้นให้ผู้รับมอบฉันทะหลายคนเพื่อแยกการลงคะแนนเสียงได้

The shareholder appointing the proxy must authorize only one proxy to attend and vote at the meeting and may not split the number of shares to several proxies for splitting votes.

2. ในกรณีที่มีวาระที่พิจารณาในการประชุมมากกว่าวาระที่ระบุไว้ข้างต้น ผู้มอบฉันทะสามารถระบุเพิ่มเติมได้ในใบประจำ
ต่อแบบหนังสือมอบฉันทะแบบ ข. ตามแนบ

In case there are any further agenda apart from those specified above brought into consideration in the meeting, the Grantor may use the Allonge of the Proxy Form B. as attached.

ใบประจำต่อแบบหนังสือมอบฉันทะแบบ ข.

Allonge of Proxy Form B

การมอบฉันทะในฐานะเป็นผู้ถือหุ้นของบริษัท โรงพยาบาลรามคำแหง จำกัด (มหาชน)

The appointment of proxy by the shareholder of Ramkhamhaeng Hospital Public Company Limited

ในการประชุมสามัญผู้ถือหุ้น ประจำปี 2569 ในวันที่ 30 เมษายน 2569 เวลา 13.00 น. ณ ห้องประชุมชั้น 10 อาคาร 3 โรงพยาบาลรามคำแหง เลขที่ 436 ถนนรามคำแหง แขวงหัวหมาก เขตบางกะปิ กรุงเทพมหานคร 10240 หรือจะพึงเลื่อนไปใน วัน เวลา และสถานที่อื่นด้วย

In the meeting of the Annual General Meeting of Shareholders for the year 2026 on April 30, 2026 at 13.00 hrs. at Meeting Room, Floor 10, Building 3 Ramkhamhaeng Hospital Public Company Limited, No. 436 Ramkhamhaeng Road, Hua Mark sub-district, Bangkapi district, Bangkok, 10240 or at any adjournment thereof to any other date, time and place.

วาระที่..... เรื่อง

Agenda Subject

(ก) ให้ผู้รับมอบฉันทะมีสิทธิพิจารณาและลงมติแทนข้าพเจ้าได้ทุกประการตามที่เห็นสมควร

(a) To grant my/our proxy to consider and vote on my/our behalf as he/she may deem appropriate in all respects.

(ข) ให้ผู้รับมอบฉันทะออกเสียงลงคะแนนตามความประสงค์ของข้าพเจ้าดังนี้

(b) To grant my/our proxy to vote at my/our desire as follows:

เห็นด้วย

ไม่เห็นด้วย

งดออกเสียง

Approve

Disapprove

Abstain

วาระที่..... เรื่อง

Agenda Subject

(ก) ให้ผู้รับมอบฉันทะมีสิทธิพิจารณาและลงมติแทนข้าพเจ้าได้ทุกประการตามที่เห็นสมควร

(a) To grant my/our proxy to consider and vote on my/our behalf as he/she may deem appropriate in all respects.

(ข) ให้ผู้รับมอบฉันทะออกเสียงลงคะแนนตามความประสงค์ของข้าพเจ้าดังนี้

(b) To grant my/our proxy to vote at my/our desire as follows:

เห็นด้วย

ไม่เห็นด้วย

งดออกเสียง

Approve

Disapprove

Abstain

วาระที่..... เรื่อง

Agenda Subject

(ก) ให้ผู้รับมอบฉันทะมีสิทธิพิจารณาและลงมติแทนข้าพเจ้าได้ทุกประการตามที่เห็นสมควร

(a) To grant my/our proxy to consider and vote on my/our behalf as he/she may deem appropriate in all respects.

(ข) ให้ผู้รับมอบฉันทะออกเสียงลงคะแนนตามความประสงค์ของข้าพเจ้าดังนี้

(b) To grant my/our proxy to vote at my/our desire as follows:

เห็นด้วย

ไม่เห็นด้วย

งดออกเสียง

Approve

Disapprove

Abstain

วาระที่..... เรื่อง

Agenda Subject

(ก) ให้ผู้รับมอบฉันทะมีสิทธิพิจารณาและลงมติแทนข้าพเจ้าได้ทุกประการตามที่เห็นสมควร

(a) To grant my/our proxy to consider and vote on my/our behalf as he/she may deem appropriate in all respects.

(ข) ให้ผู้รับมอบฉันทะออกเสียงลงคะแนนตามความประสงค์ของข้าพเจ้าดังนี้

(b) To grant my/our proxy to vote at my/our desire as follows:

เห็นด้วย

ไม่เห็นด้วย

งดออกเสียง

Approve

Disapprove

Abstain

ข้าพเจ้าขอรับรองว่า รายละเอียดในใบประจำต่อแบบหนังสือมอบฉันทะแบบ ถูกต้องสมบูรณ์และเป็นความจริงทุกประการ

I/We hereby confirm that the details in the Allonge of Proxy Form B is correct in all respects

ลงชื่อ.....ผู้มอบฉันทะ

Sign Grantor

(.....)

ลงชื่อ.....ผู้รับมอบฉันทะ

Sign Proxy

(.....)

ลงชื่อ.....ผู้รับมอบฉันทะ

Sign Proxy

(.....)

ลงชื่อ.....ผู้รับมอบฉันทะ

Sign Proxy

(.....)

หนังสือมอบฉันทะแบบ ค.

PROXY Form C.

(สำหรับผู้ถือหุ้นที่เป็นนักลงทุนต่างประเทศและแต่งตั้งให้คัสโตเดียนในประเทศไทย
เป็นผู้รับฝากและดูแลหุ้นเท่านั้น)

(For foreign shareholders who have Custodian in Thailand only)

อากรแสตมป์

Stamp Duty

20 บาท/Baht

เขียนที่

Written at

วันที่.....เดือน.....พ.ศ.

Date Month Year

(1) ข้าพเจ้า

I / We

สำนักงานตั้งอยู่เลขที่ถนน ตำบล/แขวง

Residing at no. Road Tambon/Khwaeng

อำเภอ/เขต จังหวัด รหัสไปรษณีย์

Amphur Province Postcode

ในฐานะผู้ประกอบการธุรกิจเป็นผู้รับฝากและดูแลหุ้นให้กับ.....

acting as the Custodian for

ซึ่งเป็นผู้ถือหุ้นของ บริษัท โรงพยาบาลรามคำแหง จำกัด (มหาชน) โดยถือหุ้นรวมทั้งสิ้น

being a shareholder of Ramkhamhaeng Hospital Public Company Limited, holding the total amount of share(s)

และออกเสียงลงคะแนนได้เท่ากับ เสียง ดังนี้

and having voting rights equivalent to vote(s), the details of which are as follows :

หุ้นสามัญ	หุ้น	ออกเสียงลงคะแนนได้เท่ากับ	เสียง
Ordinary share	share(s),	having voting rights equivalent to	vote(s)
หุ้นบุริมสิทธิ	หุ้น	ออกเสียงลงคะแนนได้เท่ากับ	เสียง
preferred share	share(s),	having voting rights equivalent to	vote(s)

(2) ขอมอบฉันทะให้

hereby authorize

(1) อายุ ปี อยู่บ้านเลขที่
age residing at No.

ถนน ตำบล/แขวง อำเภอ/เขต

Road Sub-District District

จังหวัด รหัสไปรษณีย์ หรือ

Province Postcode OR

(2) อายุ ปี อยู่บ้านเลขที่

age residing at No.

ถนน ตำบล/แขวง อำเภอ/เขต

Road Sub-District District

จังหวัด รหัสไปรษณีย์ หรือ

Province Postcode OR

(3) อายุ ปี อยู่บ้านเลขที่

age residing at No.

ถนน ตำบล/แขวง อำเภอ/เขต

Road Sub-District District

จังหวัด รหัสไปรษณีย์

Province Postcode

คนหนึ่งคนใดเพียงคนเดียวเป็นผู้แทนของข้าพเจ้าเพื่อเข้าประชุมและออกเสียงลงคะแนนแทนข้าพเจ้าในการประชุมสามัญผู้ถือหุ้น ประจำปี 2569 ในวันที่ 30 เมษายน 2569 เวลา 13.00 น. ณ ห้องประชุมชั้น 10 อาคาร 3 บริษัท โรงพยาบาลรามคำแหง จำกัด (มหาชน) เลขที่ 436 ถนนรามคำแหง แขวงหัวหมาก เขตบางกะปิ กรุงเทพมหานคร หรือจะพึงเลื่อนไปในวัน เวลา และสถานที่อื่นด้วย

Anyone of the above as my/our proxy holder to attend and vote on my behalf at the Annual General Meeting of Shareholder for the year 2026 to be held on April 30, 2026 at 13.00 hrs. The meeting will be conducted at Meeting Room 10th floor Building 3, Ramkhamhaeng Hospital Public Company Limited, No. 436 Ramkhamhaeng Road, Hua Mark sub-district, Bangkok district, Bangkok, or at any adjournment thereof to any other date, time and place.

(3) ข้าพเจ้าได้มอบฉันทะให้ผู้รับมอบฉันทะในการเข้าร่วมประชุมและออกเสียงลงคะแนนในครั้งนี้ ดังนี้

I/We hereby authorize the proxy holder to attend the meeting and vote on my/our behalf as follows:

- มอบฉันทะตามจำนวนหุ้นทั้งหมดที่ข้าพเจ้าถือและมีสิทธิออกเสียงลงคะแนนได้
Grant proxy the total amount of shares holding and entitled to vote
- มอบฉันทะบางส่วนคือ
Grant partial shares of
 - หุ้นสามัญ หุ้น และมีสิทธิออกเสียงลงคะแนนได้ เสียง
ordinary share share(s), having voting rights equivalent to vote(s)
 - หุ้นบุริมสิทธิ..... หุ้น และมีสิทธิออกเสียงลงคะแนนได้ เสียง
preferred share share(s), having voting rights equivalent to vote(s)
- รวมสิทธิออกเสียงลงคะแนนทั้งหมด เสียง
Total voting rights vote(s)

(4) ข้าพเจ้าขอมอบฉันทะให้ผู้รับมอบฉันทะออกเสียงลงคะแนนแทนข้าพเจ้าในการประชุมครั้งนี้ ดังนี้

I/We hereby authorize the proxy holder to vote on my behalf at this meeting as follows:

วาระที่ 1 พิจารณารับรองรายงานการประชุมวิสามัญผู้ถือหุ้น ครั้งที่ 1/2568 เมื่อวันที่ 10 มิถุนายน 2568

Agenda 1: To consider and certify the minutes of meeting of the Extraordinary General Meeting of Shareholders No. 1/2025 on June 10, 2025

- (ก) ให้ผู้รับมอบฉันทะมีสิทธิพิจารณาและลงมติแทนข้าพเจ้าได้ทุกประการตามที่เห็นสมควร
- (a) To grant my/our proxy to consider and vote on my/our behalf as he/she may deem appropriate in all respects.
- (ข) ให้ผู้รับมอบฉันทะออกเสียงลงคะแนนตามความประสงค์ของข้าพเจ้าดังนี้
- (b) To grant my/our proxy to vote at my/our desire as follows:
- | | | |
|-----------------------------------|--------------------------------------|-------------------------------------|
| <input type="checkbox"/> เห็นด้วย | <input type="checkbox"/> ไม่เห็นด้วย | <input type="checkbox"/> งดออกเสียง |
| Approve | Disapprove | Abstain |

วาระที่ 2 รับทราบรายงานผลการดำเนินงานประจำปี 2568

Agenda 2: To acknowledge the report on the results of operations for the year 2025

วาระที่ 3 พิจารณานุมัติงบการเงินสำหรับปี สิ้นสุด ณ วันที่ 31 ธันวาคม 2568 ซึ่งผ่านการตรวจสอบโดยผู้สอบบัญชีรับอนุญาตแล้ว

Agenda 3: To consider and approve the Financial Statements for the year ended 31 December 2025 which have been audited by an authorized auditor

- (ก) ให้ผู้รับมอบฉันทะมีสิทธิพิจารณาและลงมติแทนข้าพเจ้าได้ทุกประการตามที่เห็นสมควร
- (a) To grant my/our proxy to consider and vote on my/our behalf as he/she may deem appropriate in all respects.
- (ข) ให้ผู้รับมอบฉันทะออกเสียงลงคะแนนตามความประสงค์ของข้าพเจ้าดังนี้
- (b) To grant my/our proxy to vote at my/our desire as follows:
- | | | |
|-----------------------------------|--------------------------------------|-------------------------------------|
| <input type="checkbox"/> เห็นด้วย | <input type="checkbox"/> ไม่เห็นด้วย | <input type="checkbox"/> งดออกเสียง |
| Approve | Disapprove | Abstain |

วาระที่ 4 พิจารณานุมัติการจ่ายเงินปันผล ประจำปี 2568

Agenda 4: To consider and approve the dividend payment for the year 2025

- (ก) ให้ผู้รับมอบฉันทะมีสิทธิพิจารณาและลงมติแทนข้าพเจ้าได้ทุกประการตามที่เห็นสมควร
- (a) To grant my/our proxy to consider and vote on my/our behalf as he/she may deem appropriate in all respects.
- (ข) ให้ผู้รับมอบฉันทะออกเสียงลงคะแนนตามความประสงค์ของข้าพเจ้าดังนี้
- (b) To grant my/our proxy to vote at my/our desire as follows:
- | | | |
|-----------------------------------|--------------------------------------|-------------------------------------|
| <input type="checkbox"/> เห็นด้วย | <input type="checkbox"/> ไม่เห็นด้วย | <input type="checkbox"/> งดออกเสียง |
| Approve | Disapprove | Abstain |

วาระที่ 6 พิจารณานุมัติค่าตอบแทนกรรมการ ประจำปี 2569

Agenda 6: To consider and approve the directors' remuneration for the year 2026

- (ก) ให้ผู้รับมอบฉันทะมีสิทธิพิจารณาและลงมติแทนข้าพเจ้าได้ทุกประการตามที่เห็นสมควร
- (a) To grant my/our proxy to consider and vote on my/our behalf as he/she may deem appropriate in all respects.
- (ข) ให้ผู้รับมอบฉันทะออกเสียงลงคะแนนตามความประสงค์ของข้าพเจ้าดังนี้
- (b) To grant my/our proxy to vote at my/our desire as follows:
- | | | |
|-----------------------------------|--------------------------------------|-------------------------------------|
| <input type="checkbox"/> เห็นด้วย | <input type="checkbox"/> ไม่เห็นด้วย | <input type="checkbox"/> งดออกเสียง |
| Approve | Disapprove | Abstain |

วาระที่ 7 ให้สัตยาบันค่าตอบแทนผู้สอบบัญชี ประจำปี 2568

Agenda 7: To ratify the audit fee for 2025

- (ก) ให้ผู้รับมอบฉันทะมีสิทธิพิจารณาและลงมติแทนข้าพเจ้าได้ทุกประการตามที่เห็นสมควร
- (a) To grant my/our proxy to consider and vote on my/our behalf as he/she may deem appropriate in all respects.
- (ข) ให้ผู้รับมอบฉันทะออกเสียงลงคะแนนตามความประสงค์ของข้าพเจ้าดังนี้
- (b) To grant my/our proxy to vote at my/our desire as follows:
- | | | |
|-----------------------------------|--------------------------------------|-------------------------------------|
| <input type="checkbox"/> เห็นด้วย | <input type="checkbox"/> ไม่เห็นด้วย | <input type="checkbox"/> งดออกเสียง |
| Approve | Disapprove | Abstain |

วาระที่ 8 พิจารณานุมัติการแต่งตั้งผู้สอบบัญชีและกำหนดค่าตอบแทนผู้สอบบัญชี ประจำปี 2569

Agenda 8: To consider and approve the appointment of auditor and the audit fee for 2026

- (ก) ให้ผู้รับมอบฉันทะมีสิทธิพิจารณาและลงมติแทนข้าพเจ้าได้ทุกประการตามที่เห็นสมควร
- (a) To grant my/our proxy to consider and vote on my/our behalf as he/she may deem appropriate in all respects.
- (ข) ให้ผู้รับมอบฉันทะออกเสียงลงคะแนนตามความประสงค์ของข้าพเจ้าดังนี้
- (b) To grant my/our proxy to vote at my/our desire as follows:
- | | | |
|-----------------------------------|--------------------------------------|-------------------------------------|
| <input type="checkbox"/> เห็นด้วย | <input type="checkbox"/> ไม่เห็นด้วย | <input type="checkbox"/> งดออกเสียง |
| Approve | Disapprove | Abstain |

วาระที่ 9 พิจารณาวาระอื่นๆ (ถ้ามี)

Agenda 9: To consider other matters (if any)

- (ก) ให้ผู้รับมอบฉันทะมีสิทธิพิจารณาและลงมติแทนข้าพเจ้าได้ทุกประการตามที่เห็นสมควร
- (a) To grant my/our proxy to consider and vote on my/our behalf as he/she may deem appropriate in all respects.

(ข) ให้ผู้รับมอบฉันทะออกเสียงลงคะแนนตามความประสงค์ของข้าพเจ้าดังนี้

(b) To grant my/our proxy to vote at my/our desire as follows:

เห็นด้วย

Approve

ไม่เห็นด้วย

Disapprove

งดออกเสียง

Abstain

(5) การลงคะแนนเสียงของผู้รับมอบฉันทะในวาระใดที่ไม่เป็นไปตามที่ระบุไว้ในหนังสือมอบฉันทะนี้ ให้ถือว่าการลงคะแนนเสียงนั้นไม่ถูกต้องและไม่ใช่เป็นการลงคะแนนเสียงของข้าพเจ้าในฐานะผู้ถือหุ้น

Voting of the proxy holder in any agenda that is not specified in this proxy shall be considered as invalid and not my/our voting as a shareholder.

(6) ในกรณีที่ข้าพเจ้าไม่ได้ระบุความประสงค์ในการออกเสียงลงคะแนนในวาระใดไว้หรือระบุไว้ไม่ชัดเจนหรือในกรณีที่ที่ประชุมมีการพิจารณาหรือลงมติในเรื่องใดนอกเหนือจากเรื่องที่ระบุไว้ข้างต้น รวมถึงกรณีที่มีการแก้ไขเปลี่ยนแปลงหรือเพิ่มเติมข้อเท็จจริงประการใดให้ผู้รับมอบฉันทะมีสิทธิพิจารณาและลงมติแทนข้าพเจ้าได้ทุกประการตามที่เห็นสมควร

In case I/We have not declared a voting intention in any agenda or my/our determination is not clear or in case the meeting considers or passes resolutions in any matters apart from those agenda specified above, including the case that there is any amendment, modification or addition of any fact, the proxy holder shall have the right to consider and vote as to his/her consideration.

กิจการใดที่ผู้รับมอบฉันทะได้กระทำไปในการประชุม เว้นแต่กรณีที่มีผู้รับมอบฉันทะไม่ออกเสียงตามที่ข้าพเจ้าระบุในหนังสือมอบฉันทะนี้ให้ถือเสมือนว่าข้าพเจ้าได้กระทำการเองทุกประการ

Any business carried by the proxy holder in the said meeting, except the proxy holder does not vote as I/we specify in the proxy form, shall be deemed as having been carried out by myself/ourselves in all respects.

ลงชื่อ / Signed ผู้มอบฉันทะ / Grantor
(.....)

ลงชื่อ / Signed ผู้รับมอบฉันทะ / proxy
(.....)

ลงชื่อ / Signed ผู้รับมอบฉันทะ / proxy
(.....)

ลงชื่อ / Signed ผู้รับมอบฉันทะ / proxy
(.....)

หมายเหตุ

1. หนังสือมอบฉันทะแบบ ค. นี้ ใช้เฉพาะกรณีผู้ถือหุ้นที่ปรากฏชื่อในทะเบียนเป็นผู้ลงทุนต่างประเทศและแต่งตั้งให้คัสโตเดียน (Custodian) ในประเทศไทยเป็นผู้รับฝากและดูแลหุ้นให้เท่านั้น

This Proxy Form C. shall be applicable only for the Shareholders listed in the share register book as the foreign investors and appointed a custodian in Thailand to be responsible for safeguarding shares only.

2. หลักฐานที่ต้องแนบพร้อมกับหนังสือมอบฉันทะ คือ

Documents and evidences to be enclosed with the proxy form are:

- (1) หนังสือมอบอำนาจจากผู้ถือหุ้นให้คัสโตเดียน (Custodian) เป็นผู้ดำเนินการลงนามมอบฉันทะแทน

Power of attorney form the shareholder authorizes a Custodian to sign the Proxy Form on behalf of the shareholder.

- (2) หนังสือยืนยันว่าผู้ลงนามในหนังสือมอบฉันทะแทนได้รับอนุญาตประกอบธุรกิจคัสโตเดียน (Custodian)

Letter of certification to certify that the signer in the Proxy Form have a permit to act as a Custodian.

3. ผู้ถือหุ้นที่มอบฉันทะ จะต้องมอบฉันทะให้ผู้รับมอบฉันทะเพียงรายเดียวเป็นผู้เข้าประชุมและออกเสียงลงคะแนน ไม่สามารถแบ่งแยกจำนวนหุ้นให้ผู้รับมอบฉันทะหลายคนเพื่อแยกการลงคะแนนเสียงได้

A shareholder shall appoint only one proxy holder to attend and vote at the meeting. A shareholder may not split shares and appoint more than one proxy holder in order to split votes.

4. ในกรณีที่มิมีวาระที่จะพิจารณาในการประชุมมากกว่าวาระที่ระบุไว้ข้างต้น ผู้มอบฉันทะสามารถระบุเพิ่มเติมได้ในใบประจำต่อแบบหนังสือมอบฉันทะแบบ ค. ตามแนบ

In case that there any further agenda apart from specified above brought into consideration in the meeting, the proxy holder may use the Annex attached to Proxy Form C.

ใบประจำต่อแบบหนังสือมอบฉันทะ แบบ ค.

Annex attached to the Proxy Form C.

การมอบฉันทะในฐานะเป็นผู้ถือหุ้นของบริษัท โรงพยาบาลรามคำแหง จำกัด (มหาชน)

The appointment of proxy by the shareholder of Ramkhamhaeng Hospital Public Company Limited

ในการประชุมสามัญผู้ถือหุ้น ประจำปี 2569 ในวันที่ 30 เมษายน 2569 เวลา 13.00 น. ณ ห้องประชุมชั้น 10 อาคาร 3 โรงพยาบาลรามคำแหง เลขที่ 436 ถนนรามคำแหง แขวงหัวหมาก เขตบางกะปิ กรุงเทพมหานคร 10240 หรือจะพึงเลื่อนไปในวัน เวลา และสถานที่อื่นด้วย

In the meeting of the Annual General Meeting of Shareholders for the year 2026 on April 30, 2026 at 13.00 hrs. at Meeting Room, Floor 10, Building 3 Ramkhamhaeng Hospital Public Company Limited, No. 436 Ramkhamhaeng Road, Hua Mark sub-district, Bangkok district, Bangkok, 10240 or at any adjournment thereof to any other date, time and place.

วาระที่ เรื่อง.....

Agenda Re:

(ก) ให้ผู้รับมอบฉันทะมีสิทธิพิจารณาและลงมติแทนข้าพเจ้าได้ทุกประการตามที่เห็นสมควร

(A) The proxy holder shall be entitled to consider and resolve in lieu of me in all respects as deemed appropriate.

(ข) ให้ผู้รับมอบฉันทะออกเสียงลงคะแนนตามความประสงค์ของข้าพเจ้าดังนี้

(B) The proxy holder shall vote in accordance with my wish as follows:

เห็นด้วย.....เสียง ไม่เห็นด้วย.....เสียง งดออกเสียง.....เสียง

Approve vote(s) Disapprove vote(s) Abstain vote(s)

วาระที่ เรื่อง.....

Agenda Re:

(ก) ให้ผู้รับมอบฉันทะมีสิทธิพิจารณาและลงมติแทนข้าพเจ้าได้ทุกประการตามที่เห็นสมควร

(A) The proxy holder shall be entitled to consider and resolve in lieu of me in all respects as deemed appropriate.

(ข) ให้ผู้รับมอบฉันทะออกเสียงลงคะแนนตามความประสงค์ของข้าพเจ้าดังนี้

(B) The proxy holder shall vote in accordance with my wish as follows:

เห็นด้วย.....เสียง ไม่เห็นด้วย.....เสียง งดออกเสียง.....เสียง

Approve vote(s) Disapprove vote(s) Abstain vote(s)

ข้าพเจ้าขอรับรองว่า รายละเอียดในใบประจำต่อแบบหนังสือมอบฉันทะแบบ ถูกต้องสมบูรณ์และเป็นความจริงทุกประการ
I/We hereby confirm that the details in the Allonge of Proxy Form B is correct in all respects

ลงชื่อ.....ผู้มอบฉันทะ
Sign Grantor
(.....)

ลงชื่อ.....ผู้รับมอบฉันทะ
Sign Proxy
(.....)

ลงชื่อ.....ผู้รับมอบฉันทะ
Sign Proxy
(.....)

ลงชื่อ.....ผู้รับมอบฉันทะ
Sign Proxy
(.....)